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Abstract 
Protein biosynthesis is a vital, tightly regulated and a complex process involving a 
number of factors and enzymes. While the bacterial protein synthesis machinery is 
well understood due to the availability of various small molecule inhibitors, this is not 
true for the eukaryotic translation system. It is therefore of great interest to study small 
molecule translation inhibitors and elucidate their mode of action. This study involves 
four small molecules which target the eukaryotic translation system, i) gephyronic acid 
A, ii) des-epoxy tedanolide, iii) myriaporone 3/4, and iv) aetheramide B. 
All these compounds inhibit growth of human cancer cell lines like KB-3-1 and A-431 
in nanomolar ranges. Their cytotoxicity is attributed to the translation inhibition 
properties. In vitro and in vivo inhibition assays showed that the four substances 
inhibited translation with IC50 values in the nanomolar range. Using bicistronic vectors 
the phase of translation inhibition was assessed. Gephyronic acid A and aetheramide 
B inhibited the initiation, myriaporone 3/4 the elongation. Des-epoxy tedanolide had 
targets in both phases. A Drug Affinity Responsive Target Stability (DARTS) approach 
was used to identify the targets of gephyronic acid and myriaporone 3/4. The results 
showed that gephyronic acid and myriaporone bind directly to the eukaryotic initiation 
factor 2 alpha (eIF2α) and the eEF2 (eukaryotic elongation factor 2) kinase, 
respectively. In both cases they are the first natural compounds identified to target 
these factors. In silico modelling studies suggested that the important epoxide group 
of gephyronic acid binds to Tyr 39 and Glu 15. The binding of gephyronic acid to 
eIF2α probably inhibits eIF2α interaction with the guanidine exchange factor eIF2B 
required for conversion of eIF2α-GDP to eIF2α-GTP. Using immunofluorescence 
techniques on treated cells it was shown that des-epoxy tedanolide inhibited 
translation by inducing the phosphorylation of eIF2α and eEF2. Aetheramide B 
inhibited translation via dephosphorylation of 4E-BP, i.e. by inhibiting the mTOR 
pathway. 
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Zusammenfassung 
Proteinbiosynthese ist ein zentraler, streng regulierter und komplexer Prozess, der 
eine Reihe von Faktoren und Enzymen einschließt. Während der bakterielle 
Proteinsynthese-Mechanismus gut verstanden ist, da verschiedene kleine Moleküle 
als Translationsinhibitoren zur Verfügung stehen, ist das für das eukaryontische 
Translationssystem nicht der Fall. Es ist deshalb von großem Interesse, 
niedermolekulare Translationsinhibitoren zu erforschen und ihre Wirkweise 
aufzuklären. Diese Studie befasst sich mit vier kleinen Molekülen, die mit dem 
eukaryontischen Translationssystem interagieren, Gephyronsäure A, Des-epoxy-
Tedanolid, Myriaporon 3/4 und Aetheramid B. 
Alle diese Verbindungen hemmen das Wachstum von humanen Krebszelllinien wie 
KB-3-1 und A-431 im nanomolaren Bereich. Ihre Zytotoxizität ist auf die Translations-
hemmenden Eigenschaften zurückzuführen. Hemmtests in vitro und in vivo zeigten, 
dass die vier Substanzen die Translation mit IC50-Werten hemmen, die im 
nanomolaren Bereich liegen. Die Phase der Translationshemmung konnte mit Hilfe 
bicistronischer Vektoren bestimmt werden. Danach hemmen Gephyronsäure A und 
Aetheramid B die Initiation, Myriaporon 3/4 die Elongation. Des-epoxy-Tedanolid hat 
Zielproteine in beiden Phasen. Mit Hilfe eines Drug Affinity Responsive Target 
Stability (DARTS) Ansatzes konnten die Zielproteine von Gephyronsäure und 
Myriaporon 3/4 identifiziert werden. Die Ergebnisse zeigten, dass Gephyronsäure und 
Myriaporon direkt am eukaryontischen Initiationsfaktor 2 alpha (eIF2α) bzw. an der 
eEF2(eukaryontischer Elongationsfaktor 2)-Kinase binden. In beiden Fällen sind es 
die ersten identifizierten Naturstoffe, die mit diesen Faktoren interagieren. 
Modellierungsstudien in silico legen nahe, dass die Bindungspartner der für die 
Wirkung wichtigen Epoxidgruppe der Gephyronsäure Tyr 39 and Glu 14 sind. Die 
Bindung von Gephyronsäure an eIF2α hemmt wahrscheinlich die Interaktion mit dem 
Guanidin-Austauschfaktor eIF2B, die für die Umwandlung von eIF2α-GDP zu eIF2α-
GTP nötig ist. Mit Immunfluoreszenztechniken konnte an behandelten Zellen gezeigt 
werden, dass Des-epoxy-Tedanolid die Translation dadurch hemmt, dass es eine 
Phosphorylierung von eIF2α und eEF2 induziert. Aetheramid B wirkt über eine 
Dephosphorylierung von 4E-BP, d.h. über den mTOR-Signalweg. 
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1 Introduction 
Protein synthesis is a vital, tightly regulated and a complex process involving a 
number of factors and enzymes. These factors and enzymes catalyse the assembly of 
the ribosome subunits, mRNA templates and tRNAs (Aitken and Lorsch, 2012; Clardy, 
2006; Jackson et al., 2010; Sonenberg and Hinnebusch, 2009). The bacterial protein 
synthesis machinery is well elucidated due to the availability of various small molecule 
translation inhibitors of bacterial translation. These small molecule inhibitors have 
provided us with great insights into the structure of the ribosome and the various 
factors involved in the translation machinery. However, the scarcely available 
inhibitors of eukaryotic protein synthesis have limited our knowledge regarding the 
eukaryotic translation system (Poehlsgaard and Douthwaite, 2005; Schroeder et al., 
2007; Tu et al., 2005). Also the bacterial and eukaryotic translation machineries are 
quite distinct making it difficult to extrapolate the understanding of the prokaryotic 
translation machinery to the eukaryotes. Only a few available inhibitors of prokaryotic 
protein synthesis inhibit eukaryotic translation which tells us that the two systems are 
quite different (Schroeder et al., 2007; Sonenberg and Hinnebusch, 2009). Results 
from a large number of studies suggest that translation is dysregulated in cancer and 
a few translation inhibitors have been tested in clinical trials for cancer therapeutics 
already showing promising results (Malina et al., 2011; Silvera et al., 2010). However, 
it is a surprise that little effort has been taken to find new inhibitors of eukaryotic 
translation. Although identifying new translation inhibitors and studying their mode of 
action is a daunting task, it is well worth the effort considering their therapeutic value 
and their role in better elucidating the translation system. 
1.1 Overview of eukaryotic translation 
Translation of mRNA into its protein counterpart takes place in four well regulated 
steps viz. initiation, elongation, termination and recycling of the ribosome (Fig. 1.1). 
Translation initiation is the most important and rate limiting step of translation. It 
involves the assembly of the ribosomal subunits at the AUG start codon with the aid of 
wide range of initiation factors. In eukaryotes, initiation can be cap-dependent or cap-
independent. In elongation, the cognate charged aminoacyl tRNA binds to the 
respective codon at the acceptor (A) site. A peptide bond is formed between the 
amino acid in the A site and the amino acid at the peptidyl (P) site. Then the ribosome 
translocates to the exit (E) site leaving the A site open for the next aminoacyl tRNA. 
The process continues till a stop codon is reached leading to the termination of the 
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peptide formation. Finally, the ribosomal subunits are dissociated and recycled back 
to initiation phase (Kapp and Lorsch, 2004; Marintchev and Wagner, 2004). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Overview of translation in eukaryotes. 
Translation is divided into initiation, elongation, termination and recycling of the ribosomal 
subunits (adapted from http://www.nobelprize.org/educational/medicine/dna/a/translation/). 
 
1.2 Translation initiation 
The process of eukaryotic translation initiation involves the assembly of 40S and the 
60S ribosome to form an elongation competent 80S ribosome along with initiator 
methionyl transfer RNA (Met-tRNAi) at the P site on the start codon (AUG). This tightly 
regulated assembly takes place with the help of 12 eukaryotic initiator factors (eIFs) at 
least in the case of cap-dependent translation. The established mechanism of the 
initiation process can be divided into: i) formation of the ternary complex, ii) formation 
of the 43S preinitiation complex (PIC), iii) attachment of the 43S PIC to the mRNA, iv) 
scanning of the mRNA untranslated regions (UTRs) and identification of the start 
codon and v) joining the ribosomal subunits (Fig. 1.2) (Aitken and Lorsch, 2012; 
Jackson et al., 2010; Van Der Kelen et al., 2009). These stages of the initiation 
process are described in detail in the following sections. 
Recycling 
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Figure 1.2: Overview of translation in eukaryotes. 
eIF2-GTP binds to the methionyl transfer RNA (fMet-tRNAi) to form the ternary complex. The 
ternary complex then binds to the 40S ribosomal subunit to form the 43S complex. The eIF4F 
complex containing eIF4E, eIF4A and eIF4G binds to the 5’mRNA cap along with eIF4B. The 
eIF4 complex unwinds the secondary structures of the mRNA and recruits the mRNA to the 
43S complex to form the 43S preinitiation complex (PIC). The PIC then scans the mRNA to 
locate the start AUG codon. Once the codon is reached eIF2-GTP undergoes hydrolysis and 
releases the tRNAi.  eIF5B helps in releasing of the initiation factor and the 60S subunit joins 
the 40S subunit to form the elongation competent initiation complex (modified from Klann and 
Dever, 2004). 
 
GTP, Met-
tRNAiMet 
GDP 
eIF2B 
eIFs 
eIF2 
GDP 
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1.2.1 Formation of the ternary complex 
The Met-tRNAi (first amino acid) is brought in by eIF2. eIF2 is a heteromer consisting 
of the α, β and γ subunits with a total molecular mass of 126 kDa. The γ subunit of the 
eIF2 complex is homologous to the eEF1A (Kapp and Lorsch, 2004; Naranda et al., 
1995). Unlike eEF1A, which binds to all the tRNAs with the same affinity, eIF2 binds 
specifically to Met-tRNAi through the γ subunit. The γ subunit interacts directly with the 
GTP and the tRNA as shown by footprinting data. The specificity arises due to subtle 
differences which include three consecutive G:C pairing in the anti-codon stem, 
conserved sequences around the T loop, base pairing of A1:U72 at the acceptor 
stem, and modification of the phosphoribosyl unit at  position 64 (Astrom et al., 1993). 
Of these the acceptor stem modification seems to be the most important for 
differentiating a tRNA into an initiator tRNA whereas the change at position 64 
reduces the affinity of eEF1A for initiator tRNA (Fig. 1.3) (Drabkin et al., 1998). Met-
tRNAi has a higher affinity for eIF2-GTP than for eIF2-GDP. The conversion of eIF2-
GDP to eIF2-GTP takes place with the help of the guanine exchange factor eIF2B. 
This conversion is a well regulated stage in translation (Sonenberg and Hinnebusch, 
2009). eIF2B, a heteropentamer consists of α, β, γ, δ, and ε subunits with a molecular 
mass of ~263 kDa. The catalytic subunits are δ and ε, which are responsible for 
guanine exchange. The other subunits form the regulatory unit of eIF2B 
(Stolboushkina and Garber, 2011). 
 
 
 
 
 
 
 
Figure 1.3: Structure of eukaryotic tRNA.  
The boxes indicate unique features of the initiator tRNA and the arrows the mutation in the 
tRNA to differentiate the initiator tRNA from the elongation tRNAs (adapted from Drabkin et al, 
1997). 
G1 C72 
A29 
U31 
U41 
U39 
U60 
U54 
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90° turn 
180° turn 
1.2.2 Formation of the 43S preinitiation complex 
The next in the initiation process is the formation of a 43S preinitiation complex (PIC). 
The ribosome required for the complex is acquired from recycling of the post 
termination complex. Formation of 43S preinitiation complex requires a pool of 
detached 40S and 60S ribosome subunits. Physiological conditions in the cell favour 
the association of the 40S and the 60S ribosomal subunits to form the 80S ribosome. 
Therefore it is necessary to dissociate the subunits (Jackson et al., 2010). The intact 
80S ribosome from the post termination complex (TC) is still bound to mRNA, tRNA 
and the eukaryotic release factor 1 (eRF1) (Pisarev et al., 2007). The dissociation of 
the 80S ribosome into the 40S and 60S subunits and the removal of the bound mRNA 
and eRF1 takes place with the help of eIF3, eIF1 and eIF1A (Preiss and M, 2003). 
The binding of eIF3j induces the release of the tRNA from the post TC. eIF3, eIF1 and 
eIF1A remain bound to the 40S subunit to prevent re-attachment of the subunits. 
eIF3, eIF1 and eIF1A along with eIF5 promote the attachment of the ternary complex 
to the 40S ribosomal subunit forming the 43S preinitiation complex. Studies have 
shown that eIF3 binds near the P site and eIF1A binds near the A site of the 43S 
complex. The ternary complex is positioned at the P site. As eIF3 is a multimeric 
protein, it is equivalent to the 40S subunit in size and interacts with almost every 
component in the preinitiation complex (Fig. 1.4). It has been hypothesised that eIF3, 
eIF1A and eIF2 interact with each other to stabilise the ternary complex (Asano et al., 
2000; Olsen et al., 2003; Phan et al., 1998).  
 
 
 
 
 
 
Figure 1.4: Formation of PIC.  
The two figures on the top show the positioning of the tRNAi and the initiation factors and the 
bottom panel shows the interactions of the initiation factors with the 40S subunit (adapted from 
Aitken and Lorsch, 2012). 
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1.2.3 Attachment of the 43S PIC to the mRNA 
The 43S PIC formation is followed by the recruitment of the mRNA to the complex. 
The 5’ untranslated regions (UTRs) of the mRNA possess many secondary structures 
which hinder the loading of the 43S preinitiation complex onto the mRNA. The 
unwinding of the secondary structures and recognition of the 5’ UTRs of the mRNA 
takes places with the help of the eIF4F, eIF4B and poly (A) binding protein (PABP) 
(Fig. 1.5) (Pestova and Kolupaeva, 2002). eIF4F is a multimeric protein composed of 
eIF4E, eIF4A and eIF4G. eIF4E, the smallest part of the eIF4F complex is a monomer 
of 25 kDa. eIF4E specifically recognises the 5’ end and binds to the m7GpppG5’ cap 
structure of the UTR mRNA (Marcotrigiano et al., 1999). eIF4A is a monomeric protein 
with a molecular mass of 46 kDa. It belongs to the family of DEAD box RNA helicases 
and unwinds the secondary structures in the UTRs of the mRNA. Like other helicases 
eIF4A it is an RNA dependant ATPase and therefore uses the energy from ATP to 
unwind the RNA. On its own, eIF4A is a week ATPase and requires the help of eIF4B 
and eIF4G to enhance its ATPase activity (Bi and Goss, 2000; Rogers et al., 2002).  
  
 
 
 
 
Figure 1.5: Loading of the PIC 
The mRNA has many secondary structures and as a result the 43S complex cannot bind to it. 
However, eIF4A along with eIF4B unwinds the secondary structures in the mRNA attached to 
eIF4E and eIF4G, and forms the activated mRNP. The activated mRNP then binds to the 43S 
complex to form the 43S PIC. The eIF3 bound to the 43S complex interacts with eIF4G and 
stabilises the PIC (adapted from Aitken and Lorsch, 2012). 
 
eIF4G is the largest part and the centrepiece of the eIF4F complex as it binds to 
eIF4E, eIF4A, 43S complex, PABP, eIF3 and the mRNA. It forms a bridge between 
the 5’ cap of the mRNA and the 40S subunit. The eIF4G – eIF3 interaction brings the 
43S complex and the mRNA together (De Gregorio et al., 1999; Morino et al., 2000) 
(Fig. 1.5). 
Secondary structures 
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1.2.4 Scanning of the mRNA UTRs and identification of the start codon 
Once the 43S complex has attached to the 5’ cap it begins to scan the mRNA 
downstream of the cap. The term scanning was coined by Kozak (Kozak, 1999). 
Scanning involves unwinding the secondary structures at the 5’ cap and movement of 
the ribosome along the mRNA from the 5’ end to the 3’ end. It has been shown that 
the 43S complex can move along the unstructured mRNA without the help of the 
initiation factors. However, the complex does not have the ability to reach the AUG 
codon without the help of eIF1 and eIF1A (Passmore et al., 2007; Pestova and 
Kolupaeva, 2002). This suggests that the conformation induced by eIF1 and eIF1A is 
necessary for the scanning process. Experiments have also shown that the scanning 
is an energy consuming process. The energy is supplied in the form of ATP. Apart 
from ATP the scanning process also requires eIF4G, eIF4A and eIF4B. It is clear that 
eIF4F complex is not only required for the recruitment of the mRNA but also for 
scanning it (Jackson, 1991; Svitkin et al., 2001). 
Although the molecular mechanism of scanning is still unclear two mechanisms have 
been proposed in an attempt to explain the actual process. According to the Brownian 
ratchet model, the eIF4 complex is bound to the E site of the 43S complex, i.e., the 
trailing end. This prevents the ribosome from sliding backwards. As a result eIF4A 
acts as the helicase and the 40S subunit unwinds the mRNA by itself. This model is 
supported from the cryoelectron microscopy images which show the eIF4G bound 
downstream of the scanning direction, at the E site (Siridechadilok et al., 2005; Spirin, 
2009). In the second model, it has been proposed that the eIF4A and eIF4B are 
present ahead of the PIC and unwinds the secondary structures. Backsliding is 
prevented by the formation of the secondary structures in the downstream region just 
behind the E site. In either of the models, the 40S subunit movement is assumed to 
proceed via diffusion (Marintchev et al., 2009; Pisarev et al., 2008). However, what 
actually might be going on during scanning still requires more study probably with 
small molecules, electron microscopy, etc. (Aitken and Lorsch, 2012). 
Once the PIC starts scanning it is now competent to recognise the start codon. The 
actual model of start codon recognition was proposed by Kozak (Kozak, 1999). 
According to his model, the PIC identifies the first AUG closest to the 5’ end. To 
ensure the fidelity of start codon identification the consensus sequence 
GCC(A/G)CCAUGG aids the whole process. The fidelity of the start codon recognition 
is maintained by eIF1. eIF1 ensures that the PIC differentiates between the correct 
AUG codon (marked by the consensus sequence) and the false AUG codons. A wide 
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range of studies have shown that eIF1 plays an acute role in start codon selection 
(Kozak, 1991; Pestova et al., 1998). Various proposed models explain the codon 
selection and base-paring, however, the Pestova and Kolupaeva model has wide 
acknowledgement. According to this model, the 43S complex in association with the 
eIF1 and eIF1A forms the ‘open’ complex. This complex favours the scanning process 
(Pestova and Kolupaeva, 2002). To form a stable codon anti-codon base pairing, the 
‘closed’ conformation of the ribosomal complex has to be attained. This is 
accomplished by tightening of the eIF1A and 40S subunit bonding along with the 
detachment of the eIF1 from the P site. In the ‘closed’ state the anticodon tRNA is in 
the predisposed state to form the base pairing with the AUG codon on the mRNA. 
Also, this induces the Pi release from the eIF2 complex, converting the eIF2-GTP to 
eIF2-GDP. The hydrolysis of GTP to GDP takes place with the help of eIF5, a GTP 
activating protein dedicated to eIF2. The GTP hydrolysis leads to a reduction in the 
affinity of eIF2 for the Met-tRNAi. As a result eIF2 is partially displaced from the 40S 
ribosomal subunit and the already predisposed tRNAi base pairs with the start codon 
(Kapp and Lorsch, 2004; Maag et al., 2006; Maag et al., 2005). 
1.2.5 Joining the ribosomal subunits 
The final step in the translation initiation is the joining of the 40S and 60S ribosomal 
subunits. However, the joining of the ribosomal subunits can take place only after all 
the initiation factors have dissociated from the mRNA-ribosome complex. The 
dissociation of the initiation factors eIF1, eIF1A, eIF2 and eIF3 are promoted by the 
GTP hydrolysing eIF5B (Pestova et al., 2000). Once the tRNAi is base paired with the 
right codon, 60S subunit joining to the 40S subunit is automatically induced to form 
the 80S ribosome. The subunit joining prompts the eIF5B to hydrolyse GTP inducing a 
conformational change in the 80S ribosome. The GDP-eIF5B then freely dissociates 
from the 80S ribosome. After the release of the bound factors, the 80S ribosome 
along with the tRNAi and the mRNA form the 80S initiation complex which is ready for 
the elongation phase of protein synthesis (Acker et al., 2009; Kapp and Lorsch, 2004; 
Poyry et al., 2007). 
1.2.6 Cap-independent translation initiation 
About 20 years ago, it was discovered that mRNA from picornavirus was translated 
quite differently from the cap-dependent translation. The ribosome was loaded onto a 
highly structured 5’ cap region of the mRNA which initiated translation then. These 
highly structured regions of the viral mRNA were named Internal Ribosome Entry 
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Sites (IRES) (Balvay et al., 2009). The experimental evidence that picornavirus could 
translate in a cap-independent fashion was provided by tests with 
encephalomyocarditis virus (EMCV) and poliovirus (Jang et al., 1988; Nomoto et al., 
1976). In these studies the 5’ UTRs from these viruses were placed into a bicistronic 
vector where one of the cistrons had 5’ UTRs from the cap-dependent translation 
system. The translation of the cap-dependent UTR was inhibited whereas the 5’ viral 
UTR translation proceeded without any hindrance. Since then it has become clear that 
translation can also proceed in a cap-independent fashion.  
Initially it was believed that the IRES elements could arise only from the viral mRNA 
but later studies led to the discovery of IRES elements even from the cellular mRNA. 
The first cellular IRES identified was that of BiP, an immunoglobulin heavy chain 
binding protein. The proteins translated via cellular IRES include a few translation 
initiation factors, survival proteins, oncogenes, etc. As of now 80 cellular IRES and 56 
viral IRES have been studied (Baird et al., 2006; Mokrejs et al., 2006; Sarnow, 1989). 
Depending on the dispensability of the initiation factors and the secondary structures 
of the 5’ UTR the viral IRES can be divided into Type 1 and 2 belonging to the 
picornavirus family, Type 3 of the flavivirus family and Type 4 of the dicistroviral family 
(Jackson et al., 2010). 
 
 
 
 
 
 
 
 
Figure 1.6: Type 1 and type 2 IRES  
Type 1 and type 2 IRES belong to the picornoviral family. Both the IRES do not require eIF4E. 
The 43S complex is only recruited with the help of eIF4A and eIF4G (adapted from Jackson et 
a.,l 2010). 
Dispensable 
initiation factors 
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From the experimental data the picornoviral IRES was divided into type 1 as found in 
poliovirus and type 2 as in EMCV. Type 1 IRES elements use the second AUG codon 
100 to 150 nucleotides downstream of a polypyrimidine region in the vicinity of the first 
codon whereas in the type 2 IRES the ribosome is loaded directly on the AUG codon 
20 to 25 nucleotides downstream of the pyrimidine rich region. Experiments using 
reconstituted rabbit reticulocytes lysates identified that eIF4E and eIF4G were 
dispensable to the type 1 and 2 IRES elements, whereas all the other initiation factors 
were absolutely necessary for the translation (Balvay et al., 2009; Jang, 2006).  
 
 
 
 
 
 
 
 
Figure 1.7: HCV IRES 
Panel A shows the secondary structures of type 3 IRES from HCV (adapted from Balvay et al., 
2009). Panel B shows the HCV’s requirement for the initiation factors for translation initiation 
(adapted from Jackson et a.,l 2010.) 
 
Members of flaviviral family include hepatitis C virus (HCV), bovine viral diarrhoea 
virus (BVDV), etc. The well characterised IRES of this family is that of HCV (Wang et 
al., 1993). It has a 341 nucleotide long 5’ UTR and lacks the cap structure. As can be 
seen from Fig. 1.7A, these 341 nucleotides are highly structured into four domains. 
The start codon AUG is at position 342. The domains II, III and IV are essential for the 
IRES activity. In fact, the domain IV extends into the start codon. Once again with the 
use of rabbit reticulocyte lysates it was shown that type 2 does not require eIF4A, 
eIF4b and eIF4F for the ribosome loading. The ternary complex recruited via eIF3’s 
interaction with domain IV and the IRES interacts directly with the 40S subunit. The 
IRES also plays a role in positioning the start codon in the P site by its direct 
A B 
40S 
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interaction with the 43S complex. Then eIF5B hydrolyses eIF2-GTP to eIF2-GDP thus 
releasing the tRNAi and allowing the joining of the 60S and the 40S subunits to form a 
translation elongation competent 80S initiation complex (Reynolds et al., 1996; 
Reynolds et al., 1995). 
The last of the IRES types, type 4, belongs to the dicistrovirus. The examples of this 
class of IRES are cricket paralysis virus (CrPV), Drosophila C virus (DCV), etc. The 
dicistrovirus has two ORFs (open reading frames) separated by an intergenic region 
(IGR). The IGR region is approximately 200 nucleotides in length. The IRES following 
the IGR is capable of initiating translation at CAA codon using glutamine as the 
initiator amino acid. The IGR has three pseudoknot (PK) domain structures: PKI, PKII, 
and PKIII (Fig. 1.8) (Balvay et al., 2009; Reavy and Moore, 1983; Wilson et al., 2000). 
Crystallographic studies revealed that the CrPV IGR IRES includes the tRNAi binding 
E and P site. The CrPV IRES is quite distinct from the other IRES types in that it 
requires none of the initiation factors, the Met-tRNAi or energy in the form of GTP 
hydrolysis to initiate the translation process (Costantino et al., 2008; Pestova et al., 
2004) (See Fig. 1.8, panel B). The non-requirement of Met-tRNAi is due to the 
presence of PKIII. PKIII is capable of binding to the P site of the 40S ribosome. The 
positioning of the PKIII on the P site resembles the tRNAi-mRNA conformation and 
enables recruitment of the 60S ribosome. The cytoplasmic environment is suitable for 
the joining of the two subunits. Hence, the 40S and 60S subunits join without any 
external stimulation and form an elongation competent 80S initiation complex (Balvay 
et al., 2009; Kanamori and Nakashima, 2001). 
 
 
 
 
 
Figure 1.8: CrPV IRES 
Panel A shows the secondary structures of the type 4 IRES and the interaction between the 
pseudoknot domains (adapted from Balvay et al., 2009). Panel B shows the interaction of the 
40S subunit with the type 4 IRES (adapted from Jackson et al., 2010). 
 
A) A B 
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1.2.7 Regulation of translation initiation 
Regulation of translation is vital for the cellular processes. Dysregulated translation 
can lead to various cellular disparities like cancer. In fact, it has been shown that in 
most cancers a number of initiation factors have been either up-regulated or down-
regulated (Malina et al., 2011). Hence control of protein synthesis is very important. Of 
all the steps in translation, initiation is the rate limiting step which has many layers of 
regulation. The regulation can either be directly on the initiation factors or at the 
mRNA level (Jackson et al., 2010; Kapp and Lorsch, 2004).  
Regulation of translation at the mRNA level takes place by PABP, RNA-protein 
interaction at the cap, by micro RNAs, regulation of 3’UTR, and interaction with 
proteins. The factors involved in the regulation are eIF2 and eIF4E which are parts of 
the eIF4F complex (Jackson et al., 2010). 
Initiation factor eIF2 is regulated by phosphorylation at Ser 51 of the alpha subunit. As 
mentioned in Section 1.2.1, eIF2 is only active when bound to GTP. If GTP is 
hydrolysed to GDP then eIF2-GDP has to be converted back to the eIF2-GTP form. 
This conversion takes place with the help of the guanine exchange factor eIF2B. 
eIF2B has higher affinity for the phosphorylated eIF2 than to the non-phosphorylated 
protein. Hence, eIF2B is not available for guanine exchange (Vattem and Wek, 2004; 
Zhou et al., 2008) (Fig. 1.9).  
 
 
 
 
 
 
 
Figure 1.9: Regulation of eIF2α. 
eIF2-GTP associates with the Met-tRNAi to form the ternary complex and binds to the 40S. At 
a later stage of initiation, the GTP hydrolyses to GDP and the eIF2-GDP is released. The eIF2-
GDP has to be converted back to eIF2-GTP to be active with the help of eIF2B (modified from 
Klann and Dever, 2004). 
Translation inhibition 
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eIF2 can be phosphorylated by four different kinases, viz. PKR (protein kinase R) 
which is activated by the presence of double stranded RNA, GCN2 (general control 
nonrepresed) which is activated by amino acid starvation, or UV radiation, HRI (heme 
regulated inhibitor) which is activated during hypoxia and only significant in red blood 
cells, and finally PERK, the PKR like endoplasmic reticulum kinase which is activated 
during ER stress. eIF2 phosphorylation can be induced by heat shock, UV rays, viral 
infection, nutrient deprivation, etc. (Klann and Dever, 2004). 
The second initiation factor to be regulated is eIF4E. As it is a comparatively low 
available factor among the initiation factors, it is thought to be the major rate limiting 
component of translation initiation. eIF4E can be regulated at two levels. Firstly it can 
be regulated by direct phosphorylation and secondly by altering the phosphorylation 
state of the eIF4E binding protein, 4E-BP. eIF4E can be phosphorylated by MAP 
kinase interacting Ser/Thr kinase 1 and 2 (MNK1 and MNK2) at Ser 209. This 
phosphorylation takes only place when eIF4E is bound to eIF4G. The second 
mechanism of eIF4E regulation involves its availability to form the eIF4F complex. 
When eIF4E is bound to 4E-BP it is unavailable for binding to eIF4G. If 4E-BP is 
phosphorylated it’s affinity for eIF4E is reduced (Fig. 1.10). 4E-BP can only bind to 
eIF4E when it is hypo-phosphorylated. Thus, when eIF4E is not bound to 4E-BP it is 
free to interact with eIF4G and proceed with the translation. The phosphorylation state 
of 4E-BP can be altered by various stimuli like insulin, adenoviral infection, 
interleukins, etc. (Gingras et al., 1999; Jackson et al., 2010). 
Figure 1.10: Regulation of eIF4E by phosphorylation of 4E-BP 
Both eIF4G and 4E-BP compete with each other to bind to eIF4E. However, if 4E-BP is hyper-
phosphorylated it has low affinity for eIF4E and thus eIF4E is freely available to interact with 
eIF4G to form the eIF4F complex (Gingars et al., 1999). 
 
Signalling pathways Viral infection, 
stress, etc 
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The mTOR signalling pathway can also influence the rate of translation initiation. As 
seen from Fig. 1.11, mTOR also alters the phosphorylation state of 4E-BP. mTOR 
phosphorylates the threonine residues at position 37 and 46 of 4E-BP. This 
phosphorylation is essential for phosphorylation at the C terminal end which is 
required for its inactivation. mTOR also phosphorylates ribosomal 40S protein S6 
kinase (S6K). The activated kinase phosphorylates S6 which in turn regulates mRNAs 
coding for ribosomal protein. The activated S6 can also interact with eIF3 and eIF4B. 
Thus, translation can be inhibited by inactivating mTOR as in the case of rapamycin 
(Van Der Kelen et al., 2009). 
 
 
 
 
 
 
 
 
 
Figure 1.11: Regulation of translation by mTOR pathway 
When mTOR is activated it induces phosphorylation of 4E-BP. Thus the hyper-phosphorylated 
4E-BP is dissociated from eIF4E making eIF4E freely available for forming the eIF4F complex 
(adapted from Kelen et al., 2009.) 
 
1.3 Translation elongation 
Unlike initiation, elongation is highly conserved between eukaryotes and prokaryotes. 
Much of our understanding of the eukaryotic elongation process comes from the 
bacterial machinery (Kapp and Lorsch, 2004; Rodnina and Wintermeyer, 2009). 
Elongation proceeds once the 80S elongation competent initiation complex is formed. 
In the 80S elongation competent complex, the initiator Met-tRNA is bound to the start 
AUG codon and is positioned on the P site, leaving the A site free for the entry of next 
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amino acyl tRNA (aa-tRNA). eEF1A-GTP brings in the next aa-tRNA to the empty A 
site. The eEF1A-GTP-amino acyl tRNA form the ternary complex of the elongation 
phase. eEF1A is equivalent to EF-Tu in bacteria (Dever and Green, 2012; Ogle et al., 
2001). Though any elongation ternary complex can enter the A site, fidelity is 
maintained by conformational changes in the anti-codon stem of the tRNA and the 
codon of the mRNA. The fidelity is also maintained by the hydrolysis of GTP which 
takes place only when the right aa-tRNA binds to the cognate codon (Schmeing et al., 
2011). Base pairing of the cognate aa-tRNA with the codon of the mRNA brings about 
a conformational change in three nucleotide bases in the rRNA induced. As a result 
the bases interact with the mRNA-aa-tRNA complex. This interaction initiates the 
eEF1A’s GTPase activity leading to hydrolysis of GTP to GDP and the release of aa-
tRNA from eEF1A-GDP to the A site. The eEF1A-GDP is recycled to eEF1A-GTP with 
the help of guanine exchange factor eEF1B (Dever and Green, 2012; Voorhees et al., 
2010). 
The peptide bond between the amino acid at the P site and the A site is catalysed by 
ribosomal peptidyl transferases. The deacylated tRNA remains in a P/E hybrid state. 
In this state the acceptor end is bound to the E site and the anticodon stem to the P 
site whereas the peptidyl tRNA (the tRNA on which the peptide is formed) lies in a A/P 
hybrid state. To continue with the next cycle of elongation, translocation must happen 
so that the deacylated tRNA lies completely in the E site and the peptidyl tRNA in the 
P site. The translocation also creates an empty A site for entry of the next aa-tRNA. 
Translocation is an energy consuming process and requires the employment of eEF2 
interaction which stabilises the hybrid state. eEF2-GTP hydrolysis induces a 
conformational change in the complex which promotes the translocation process (Fig. 
1.12). This cycle continues for the entire length of the mRNA till a stop codon is 
reached (Ben-Shem et al., 2011; Dever and Green, 2012; Klinge et al., 2011). 
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Figure 1.12: Mechanism of translation elongation 
The ternary elongation complex (eEF1A-GTP-aa.tRNA) binds to A site. The hydrolysis of GTP 
from eEF1A releases eEF1A from aa-tRNA. The amino acid on the aa-tRNA in the A site then 
forms a peptide with the amino acid in the P site. eEF2-GTP then promotes the translocation 
of tRNAs from A and P site into P and E site, respectively. The deacylated tRNA leaves the E 
site and the 80S subunit is ready to repeat the cycle of peptide elongation (adapted from 
Dever and Green, 2012). 
 
1.3.1 Regulation of elongation 
Elongation could be regulated at two stages, viz. i) at the recycling of eEF1A-GDP to 
eEF1A-GTP, ii) by regulating the translocation of eEF2. The first mechanism is still 
unclear and hence yet to be studied (Kapp and Lorsch, 2004). Regulation of eEF2 
can take place at two levels. eEF2 is a monomeric protein with a molecular mass of 
approximately 95 kDa. It has been shown that alterations at the diphthamide residue 
(a modified histidine found in eEF2) can alter the activity of eEF2. However, this mode 
of translation control still needs detailed studying. The other change in eEF2 that 
could lead to translation inhibition is the induction of phosphorylation of threonine 
residue at the position 56. Phosphorylation of eEF2 inhibits it from binding to the 
ribosome and hence hinders the translocation process. It was noted that this 
phosphorylation was calcium calmodulin dependant. Later studies revealed that eEF2 
was phosphorylated by a dedicated kinase, eEF2K. eEF2K is a Ca2+/calmodulin 
GTP 
GDP 
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dependant kinase. eEF2K undergoes auto-phosphorylation in a low calcium 
environment and phosphorylates eEF2. However, the mechanism is still unclear and 
needs further research (Dever and Green, 2012; Kapp and Lorsch, 2004; Kaul et al., 
2011; Ryazanov, 1987).  
1.4 Termination and recycling 
The end of the elongation cycle is marked when the elongation complex encounters a 
stop codon so that the translation machinery enters the termination phase. The stop 
codons include UAA, UGA, and UAG. These three codons do not code for any amino 
acids and therefore function as stop codons. Termination is brought by the joint 
function of eukaryote release factors, eRF1 and eRF3. eRF1 recognises the stop 
codon and induces the release of the peptidyl tRNA. eRF1 resembles the tRNA and 
consists of three domains. The middle domain is equivalent to the acceptor stem of 
the tRNA and promotes the peptidyl release. eRF3 is a GTPase and interacts with the 
C terminus of the eRF1. The eRF1-eRF3-GTp ternary complex binds to the A site via 
the middle domain of the eRF1. This interaction leads to the hydrolysis of GTP and 
finally to the peptide release from the P site. The peptidyl release is also aided by 
ABCe1/Rli1 (Dever and Green, 2012; Kapp and Lorsch, 2004) (Fig. 1.13). 
 
 
 
 
 
 
Figure 1.13: Mechanism of translation termination 
When the ribosome meets a stop codon, eRF1-eRF3-GTP binds to the A site which results in 
GTP hydrolysis to GDP and the release of eRF3. ABCE1/Rli 1 then interacts with the ribosome 
and releases the peptide (adapted from (Dever and Green, 2012)). 
 
The final stage in translation is the recycling of the ribosomal subunits back to the 
initiation phase. After the peptidyl release from the elongation complex, the ribosome 
is still bound to the deacylated tRNA in the P/E hybrid state, mRNA and eRF1. As 
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mentioned in Section 1.2.2, dissociation of 80S ribosome from the eRF1, tRNA and 
mRNA and the disjoining of the ribosome into 40S and 60 S subunits takes place with 
the help of eIF1, eIF1A and eIF3 (Korostelev et al., 2008; Weixlbaumer et al., 2008). 
1.5 Eukaryotic translation still remains elusive 
Though our understanding of the eukaryotic translation machinery has grown vastly in 
the last decade, it is quite clear that the eukaryotic translation machinery still requires 
to be studied. The scanning mechanism, the role of eEF1 and eEF2K are some 
examples where further studies are required (Kapp and Lorsch, 2004). As mentioned 
in Section 1, there is a dire need for the identification of new translation inhibitors and 
elucidation of their modes of action. 
1.6 Small molecule translation inhibitors 
Small molecule translation inhibitors have helped in elucidating the structure and 
function of the prokaryotic ribosome. They have also helped in dissecting the factors 
involved in translation. The lack of large number of small molecules that inhibit 
eukaryotic translation has limited our understanding of eukaryotic protein synthesis 
machinery (Chan et al., 2004). Small molecules can act as probes to elucidate the 
translation system. For example, rapamycin has helped us to understand the role of 
mTOR in translation. Likewise, pateamine A, a small molecule isolated from a marine 
sponge has helped in elucidating the role of eIF4A in the initiation process (Carlson, 
2010; Low et al., 2005). 
Natural products that inhibit translation also have been shown to be efficacious 
against cancer cells. Data from different studies show that various factors are 
dysregulated in cancer. As a result, translation inhibitors have been tested as anti-
cancer agents and some of them have progressed to Phase II trials (e.g. 
homoharringtonine) (Stone et al., 2009).  
It has also been shown that viruses interact with the host translation system to 
synthesise their proteins. Therefore it has been suggested that targeting the host 
translation system could be used in an anti-viral strategy. For example, 4EGi-1 which 
interrupts eIF4F ribosome interactions has been shown to be antiviral against HSV-1 
and VacV (McMahon et al., 2011).  
Considering the above points it is important to study small molecules translation 
inhibitors and elucidate their mode of action. The next section will introduce four small 
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molecules which are mainly polyketides that target the eukaryotic translation system. 
These are: i) gephyronic acid. ii) tedanolide, iii) myriaporone 3/4, and iv) aetheramide 
B. The elucidation of the modes of action of these compounds is the main subject of 
this study. 
1.6.1 Gephyronic acid 
Gephyronic acid was isolated from the myxobacterial Archangium gephyra strain 
Ar3895. It showed cytotoxicity in the mammalian cell line L-929 in nanomolar ranges. 
It also inhibited the growth of different yeasts with a MIC of ~ 2µM and most 
filamentous fungi with a MIC of 50 µM. However, it did not show any activity against 
bacteria. Feeding experiments with radioactive precursors for thymidine representing 
DNA replication, uridine representing transcription and methionine representing 
protein synthesis showed that gephyronic acid induces cell death by inhibiting protein 
synthesis. However, the mechanism of translation inhibition by the polyketide was still 
unclear (Anderl et al., 2011; Nicolas et al., 2011; Sasse et al., 1995). 
 
 
 
 
 
 
 
 
Figure 1.14: Gephyronic acid A 
The chemical structure of gephyronic acid A and the fruiting bodies of Archangium gephyra, 
the producing organism (photo curtesy Hans Reichenbach). 
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1.6.2 Tedanolide 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Structure of tedanolides 
The structure of tedanolides which are e.g. produced by the sponge Tedinia ignis (photo 
courtesy: http://soundwaves.usgs.gov/2006/11/meetings2.html). 
 
Tedanolide was isolated from the marine sponge Tedina ignis, also referred to as fire 
sponge, which is found largely in the Caribbean region. Tedanolide is a 18-membered 
macrolactone containing propionate and acetate units. Initial studies reported 
tedanolide as potent cytotoxic macrolide with an ED50 of 2.5 ng/mL in KB-3-1 cells. 
The study also reported that tedanolide arrested cells in the S phase of the cell cycle 
(Taylor, 2008). Later 13-deoxytedanolide was isolated from another sponge, Mycale 
adhaerens by Fusetani et al. (1995), which was even more potent showing an IC50 of 
94 pg/mL in murine leukaemia cells (Taylor, 2008). More recently, candidaspongiolide 
isolated from Candidaspongia sp. was reported (Meragelman et al., 2007). It differed 
from tedanolide in the region C11 to C15. Candidaspongiolide was cytotoxic with an 
IC50 of 14 ng/mL in leukaemia cells. All these tedanolides were reported to inhibit 
translation in the eukaryotes but through different mechanisms. It was reported that 
interaction of 13-desoxytedanolide with the 60S subunit of the ribosome induces a 
ribotoxic stress which led to the translation inhibition (Lee et al., 2006). However, it 
Tedina ignis 
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had been claimed that ribotoxic stress might not be completely responsible for the 
translation inhibition and further studies should be made to elucidate the mode of 
action (Trisciuoglio et al., 2008). 
1.6.3 Myriaporone 
Myriaporone 3/4 was isolated from the Mediterranean false coral Myriapora truncata 
(Fig. 1.16). The extracts from the false coral were shown to be toxic to cancer cells. 
Fractionation of the extracts led to the identification of myriaporone 3 and 4. The two 
isoforms were inseparable. Myriaporone 3/4 is it is a mixture of both isoforms (Hines 
et al., 2006). 
 
           
 
           
 
Figure 1.16: The structure of myriaporone 
The structure of myriaporone 3 and 4 which were isolated from the false coral Myriapora 
truncata (photo courtesy: http://coralmorphologic.com). 
 
Myriaporone 3/4 shows similarities in structure with tedanolide’s “southern 
hemisphere”. It has been reported that myriaporone 3/4 is a cytotoxic/cytostatic 
polyketide with an IC50 of 15 nM in leukaemia cells. Like gephyronic acid and 
tedanolide, myriaporone 3/4 is not active in bacteria. The cytotoxicity was attributed to 
its activity as a translation inhibitor (Hines et al., 2006; Taylor, 2008). However, the 
mode of action of myriaporone was still unknown and yet to be studied. 
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1.6.4 Aetheramide B 
                                                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17: The structure of aetheramides 
The structure of aetheramide A and B and the fruiting bodies of Aetherobacter rufus, the 
producing organism (photo courtesy: Alberto Plaza). 
 
Aetheramide A and B were isolated from the new myxobacterial species 
Aetherobacter rufus (Plaza et al., 2012) (Fig. 1.17). It is not a pure polyketide because 
it has two amino acids built in, valine and a rare amino acid, 3-(4-hydroxy-3-
methoxyphenyl)-2-(methylamino) propanoic acid (mNMeTyr) (Fig.1.17). Aetheramides 
showed an IC50 of 110 nM in colon cancer cell lines. This thesis deals only with the 
identification of mode action of aetheramide B. During this study it was discovered 
that aetheramide B also is a translation inhibitor. 
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1.7 Aim of the project 
The eukaryotic translation system is only partially understood and our current 
understanding is mostly a result of the extrapolation of the prokaryotic translation 
system (Poehlsgaard and Douthwaite, 2005; Schroeder et al., 2007; Tu et al., 2005). 
Translation is dysregulated in a number of diseases like cancer, Wolcott–Rallison 
Syndrome, during viral infections, etc. (Van Der Kelen et al., 2009). A better 
understanding of the translation machinery and the factors involved will help us design 
better drugs for therapeutics. Identification of new translation inhibitors specific to the 
eukaryotic system and elucidating the mode action of these compounds thus 
becomes very essential (Chan et al., 2004). 
Gephyronic acid, myriaporone 3/4, des-epoxy tedanolide and aetheramide B are four 
compounds originally isolated from natural sources. The first three polyketides were 
reported as translation inhibitors earlier and aetheramide B was identified as a 
translation inhibitor in our routine screening processes.  
This study aims at profiling the four translation inhibitors, identifying the molecular 
mechanism of translation inhibition induced by these compounds and identifying the 
possible direct targets in the translation system.  
 
 
 
 
 
Methods and Materials 
 
[26] 
 
2 Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
Bacterial incubator   Memmert 
Cell culture incubator   CO2-Auto-Zero (Heraeus) 
Flow cytometer   BD LSR II (BD Biosciences) 
Gel electrophoresis system  Mini PROTEAN system (Bio-Rad) 
Semi-dry Transfer system  Biometra 
X-ray processor   Optimax (ClassicXray) 
Light microscopy   Axiovert 35 (Zeiss) 
Fluorescence microscopy  Axioplan with Axiocam camera (Zeiss) 
UV spectrophotometer  UV 1000 (Shimadzu) 
Photometer    NanoDrop ND-1000 (NanoDrop technologies) 
Plate reader    Infinite M200 pro (Tecan) 
Centrifuges    Biofuge (Heraeus) 
5810R (Eppendorf) 
5418R (Eppendorf) 
Laminar airflow   Maxisafe 2020 (Thermo Fisher Scientific) 
Cell counter    Cedex XS (Innovatis) 
Shaker    Titramax 1000 (Heidolph) 
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2.1.2 Software 
AxioVision 3.1, SigmaPlot 12.3, Microsoft Office 2010, ChemDraw, FACS Diva 
Version 6.1.1, ImageJ,  
2.1.3 Consumables 
All consumables were purchased from Becton Dickinson, Eppendorf, Greiner, 
Macherey-Nagel, Nunc, Thermo Fisher Scientific, TPP or Roth, unless otherwise 
stated. 
2.1.4 Chemicals 
All chemicals were obtained from Alexis Biochemicals, Bayer, Becton Dickinson, 
Fluka, Gibco, Invitrogen, JT Baker, Merck, Roche Diagnostics, Thermo Fisher 
Scientific, Roth or Sigma. 
2.1.5 Antibodies/ Dyes 
Anti-eIF2α (mouse)     Cell Signalling 
Anti-phospho-eIF2α (Ser52) (rabbit)   Invitrogen 
Anti-4E-BP (rabbit)     Cell Signalling 
Anti-phospho-4E-BP (Thr37/46) (rabbit)  Cell Signalling 
Anti-mTOR (rabbit)     Cell Signalling 
Anti-phospho-mTOR (Ser2448) (rabbit)  Cell Signalling 
Anti-eEF2 (rabbit)     Cell Signalling 
Anti-phospho-eEF2 (Thr56) (rabbit)   Cell Signalling 
Anti-eEF2K (Ser366) (rabbit)    Cell Signalling 
Anti-phospho-eEF2K (rabbit)    Cell Signalling 
Anti-eIF4E (rabbit)     Epitomics 
Anti-TIA (mouse)     Santa Cruz 
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Anti-mouse antibody (rabbit)    Dianova 
Anti-rabbit antibody (goat)    Dianova 
Alexa Fluor 488 anti-rabbit (goat)   Molecular Probes  
Alexa Fluor 488 anti-mouse (rabbit)   Molecular Probes 
Alexa Fluor 549 anti-rabbit (goat)   Molecular Probes 
Alexa Fluor 549 anti-mouse (rabbit)   Molecular Probes 
Alexa Fluor 488 streptavidin    Molecular Probes 
2.1.6 Culture media 
For culturing bacteria EBS medium was used. For Saccharomyces cerevisiae YPD 
medium was used, for hyphal fungi M90 medium was used. E.coli was cultured in LB 
medium. All media components were purchased from Becton Dickinson, Fluka, 
Merck, Roth or Sigma. 
EBS (pH 7.0):  Peptone (5 g/L) 
   Proteose peptone (5 g/L) 
   Meat extract (1 g/L) 
   Yeast extract (1 g/L) 
Yeast extract (1 g/L) 
HEPES (10 g/L) 
M90 (pH 5.6):  Malt extract (30 g/L) 
Peptone (3 g/L) 
LB (pH: 7.5, 1 L) 10g Bacto-tryptone 
5g yeast extract 
10g NaCl 
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For the agar media (agar diffusion tests), 15 g/L agar added. The medium was 
prepared in distilled H2O and autoclaved immediately. The autoclaved media were 
then stored at 4 °C. The mammalian cell culture media used are listed in Table 2.1 
Table 2.1: Media used for different cell lines 
Cell line Medium Manufacturer Supplements 
A-549, L-929 MEM Gibco 10 % FBS (Lonza) 
KB-3-1, A-431 DMEM Lonza 10 % FBS (Gibco) 
MCF-7 DMEM Gibco 1X Non essential 
amino acids (Gibco) 
1.5 % insulin 
(Gibco) 
10% FBS (Lonza) 
A-498,PtK2 MEM Gibco 1X Non-essential 
amino acids (Gibco) 
1X GlutaMAX 
(Gibco) 
10% FBS (Lonza) 
HUVEC EMB-2 Lonza EMB-2 bullet kit 
NHDF FGM-2 Lonza FGM-2 bullet kit 
 
2.1.7 Buffers 
10 X SDS running buffer:  288 g glycine 
     60.4 g Tris Base 
20 g SDS 
1.8 L distilled water 
The buffer was diluted to 1X with water to make the working running buffer. 
10 X TBS buffer for western blotting (pH: 7.0): 160 g NaCl 
       4 g KCl 
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       12.2 g Tris Base 
       2 L distilled water 
The working TBS solution was prepared by diluting the 10 X buffer to 1X with water.  
TBST buffer was made by adding 1 mL Tween-20 to 1000 mL of 1 X TBS buffer. 
Blotting buffer:   25 mM Tris HCl 
    192 mM Glycine 
2.1.8 Kits 
MycoAlert ® Mycoplasma Detection Kit   Lonza 
Cell Titre Glo® ATP assay kit     Promega 
Apoptosis detection kit I     BD Biosciences 
Rabbit reticulocyte lysate (Nuclease treated)  Promega 
Wheat germ extracts      Promega 
E.coli cell extract      Promega 
Pierce® Silver stain kit     Thermo Fisher Scientific 
SuperSignal® West Pico Luminol solution   Thermo Fisher Scientific 
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2.1.9 Microorganisms and Cell Cultures 
Table 2.2: Microorganisms 
Microorganism  Abbreviations  Source  
Escherichia coli tolC  TolC  Ciba-Geigy, Basel 
Klebsiella pneumoniae  Kbp  HZI Collection  
Pseudomonas aeruginosa  Psa  ATCC 9027  
Staphylococcus aureus  Sta  HZI Collection  
Micrococcus luteus  Mcl  HZI Collection  
Candida albicans  Caa  DSM 1386  
Hansenula anomala  Hna  DSM 70 263  
Saccharomyces cerevisiae BY4741  Scc  Euroscarf  
Botrytis cinerea  Boc   DSM 877  
Pythium debaryanum  Pyd  DSM 62 946  
 
Table 2.3: Mammalian cell lines 
Cell line  Source  Species  Origin  Morphology  
A-498  DSMZ ACC 55  Human  Kidney cancer  Epithelium-like 
A-549  DSMZ ACC 107  Human Lung cancer  Epithelium-like 
NHDF  Lonza  Human Fibroblasts  Fibroblasts 
HUVEC  Lonza  Human Umbilical cord Endothelium  
KB-3-1  DSMZ ACC 158  Human Cervical cancer  Epithelium-like 
L-929  DSMZ ACC 2  Mouse  Connective tissue  Fibroblasts  
PtK2  ATCC CCL-56  Potoroo  Kidney  Epithelium-like 
U-937  DSMZ ACC5  Human Lymphoma  Monocytes  
 
 
 
 
Methods and Materials 
 
[32] 
 
2.2 Methods 
2.2.1 Working with microorganisms  
2.2.1.1. Handling  
All microbiological studies were carried out under sterile conditions. The bacteria and 
yeasts were not maintained as a continuous culture. Whenever required, the cells 
were revived from frozen samples (-20°C). The hyphal fungi were stored at 4°C as 
spore suspension cultures. To start the bacteria and yeasts, a frozen culture was 
placed in fresh medium and shaken overnight at 30 ° C. The next day, the OD was 
determined at 600 nm using a photometer. 
2.2.1.2 Agar diffusion assay 
For the agar diffusion tests complete media were used. For the bacteria EBS medium 
were used and for yeasts and hypal fungi YPD media and M90 media respectively. 
The medium (with agar) was heated in a microwave oven until the agar had melted 
and then cooled in a water bath at 50 ° C. The microorganisms were added to the 
medium at a final OD of 0.01 for bacteria and 0.1 for the yeasts. 15 mL of the 
inoculated media was then poured into Petri dishes and allowed to solidify. 20 µL of 
sample were applied to a filter paper disc (6 mm diameter) with a pipette under the 
laminar flow hood on a sterile glass plate and allowed to dry until the solvent had 
evaporated completely. Thereafter, the discs were placed on the agar plates with the 
microorganisms using forceps. The Petri dishes were then incubated at 30 ° C in a 
bacterial incubator for 1-2 days, depending on the speed of growth (usually 2 d for 
hyphal fungi and 1 d for bacteria). The diameter of inhibition zones was then 
measured. 
2.2.2 Working with mammalian cell cultures  
2.2.2.1 Cultivation 
The work with mammalian cell cultures was performed under sterile conditions. The 
required media were warmed at 37°C before using. The cells were kept in cell culture 
flasks at 37°C and 10% CO2. The media volume depended on the size of the cell 
culture flasks viz. 10 mL for 25 cm2, and 30 mL for 75 cm2 bottles. Adherent cells like 
L-929 and KB-3-1 were harvested and passaged when they were subconfluent (~ 80-
90% confluency). The cell layer was scraped with a cell scraper from the bottom of the 
vessel and the cells were suspended by repeatedly pipetting up and down with a 
sterile disposable plastic pipette. Other cell lines like MCF-7, PC-3, PtK2, A-431, 
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A-598 were trypsinised for passaging. To trypsinise the cells, the culture media was 
removed and the cell surface was rinsed once with EBSS followed by addition of 1 mL 
of trypsin. The flask was then incubated at 37°C for 5-10 minutes. The trypsinisation 
was stopped by adding fresh culture medium. Subsequently, an aliquot was 
transferred to a new cell culture flask with fresh medium.  
All cell lines were maintained up to 1 year in culture. They were then discarded and a 
new culture from a cryo-preserve was restarted. All cell cultures were semi-annually 
tested for mycoplasma using MycoAlert® Detection Kits according to the 
manufacturer’s protocol. 
2.2.2.2 Storage of cells  
For long term storage, the cells were harvested as for sub-culturing. They were then 
harvested by centrifugation (3000 rpm, 3 min), pelleted and re-suspended in 1 mL of 
freezing medium. They were transferred to cryo-tubes which were put into a freezing 
container at -70 ° C for at least 24 hours. After that the cells were maintained in a 
liquid nitrogen storage container maintained at -196 ° C. 
To reactivate the cryo preserved cells, the cells were quickly thawed at 37°C and 
seeded in 10 mL of fresh medium in a T25 flask. After one day, the cell culture 
medium was changed to remove the freezing medium completely. 
2.2.3 MTT assay 
Anti-proliferative activity was measured in 96-well plates. 60 µL of a serial dilution of 
the compound were added to 120 µL of suspended cells (50,000 cells/mL; two 
replicates). The end concentrations tested ranged from 37 µg to 0.2 ng/mL. After five 
days of incubation with the compound, the metabolic activity in each well was 
determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). 
20 µl MTT in PBS were added to a final concentration of 0.5 mg/mL and incubated for 
2 hours. MTT is reduced then by dehydrogenases of the cells to form purple formazan 
crystals. The precipitate was washed with 100 µl PBS and dissolved in 100 µl 
isopropanol containing 0.4 % hydrochloric acid. The resulting colour was measured at 
595 nm using a plate reader. 
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2.2.4 FACS analysis 
FACS was used to measure apoptosis in cells. For this assay an Apoptosis Detection 
Kit from BD biosciences was used. 
A-431 cells (~70% confluent) were treated with the inhibitors for 3, 6, 12 or 24 hours. 
Cells treated with methanol served as control. At the end of the incubation period, the 
cells were trypsinised, and resuspended in culture medium so that the final 
concentration of the cells was 1X106. The cells were then centrifuged at 1500 rpm for 
5 minutes and the supernatant was discarded. The cell pellet was washed with 1 mL 
of ice cold PBS and centrifuged again. The supernatant was discarded and to the cell 
pellet was resuspended in 1 mL of the 1 X Binding buffer. 100 µL of this cell 
suspension was pipetted into a FACS tube and incubated in the dark for 15 minutes 
with 5 µL of FITC Annexin V and 5 µL of propidium iodide (PI). Then 400 µL of 1 X 
Binding buffer was added to make up the volume to 500 µL and the samples were 
analysed in a BD LSR II FACS machine.  
2.2.5 In vitro translation assays 
In vitro translation assays were performed with rabbit reticulocyte lysates, wheat germ 
extracts or E.coli cell lysates. All the kits were purchased from Promega. 
2.2.5.1 Rabbit reticulocyte lysate 
Translation inhibition assay was performed by using the Flexi Rabbit Reticulocyte 
Lysate. Briefly, 500 ng of firefly luciferase mRNA was combined with 17.5 µL of rabbit 
reticulocyte lysate, 0.25 µL each of 1mM –Met and –Leu amino acid mixtures, 0.7 µL 
of 2.5 M KCl, 10 U RNasin, 3.3 µL of nuclease free water and 1 µL of the either 
gephyronic acid, myriaporone 3/4, des-epoxy tedanolide, aetheramide B or methanol 
to give final concentrations ranging from 100-0.001 µg/mL. Reactions were incubated 
at 30°C for 90 minutes. Luminescence was measured in a plate reader by mixing 2 µL 
of the mixture with 10 mL of the Firefly Luciferase Assay Substrate.  
2.2.5.2 Wheat germ extract 
The manufacturer’s protocol was modified a little to reduce the reaction volume. 
Briefly, 500 ng of firefly luciferase mRNA was combined with 12.5 µL of wheat germ 
extract, 2 µL of 1 mM –Met and –Leu amino acid mixtures, 3 µL of 1 M KCl, 40 U of 
RNasin, (1 µL from 40 U /µL), 3 µL of nuclease free water and 1 µL of either 
gephyronic acid, myriaporone 3/4, des-epoxy tedanolide, aetheramide B or methanol 
to give final concentrations ranging from 100-0.001 µg/mL. The reaction mix was 
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incubated at 25°C for 2 hours. Luminescence was measured in a plate reader by 
adding 2 µL of the reaction mix with 10 mL of the Firefly Luciferase Assay Substrate. 
2.2.5.3 E.coli S30 extract 
The manufacturer’s protocol was modified a little to reduce the reaction volume. 
Briefly, 1 µg of firefly luciferase control RNA provided in the kit was combined with 7.5 
µL of S30 extract, 5 µL S30 Premix Without Amino Acids, 1.5 µL of 1 mM –Met 
and -Leu amino acid mixtures, 40 U of RNasin, (1 µL from 40 U /µL), 3 µL of nuclease 
free water and 1 µL of either gephyronic acid, myriaporone 3/4, des-epoxy tedanolide, 
aetheramide B or methanol to give final concentrations ranging from 100-0.001 
µg/mL. The reaction mix was incubated at 25°C for 2 hours. Luminescence was 
measured in a plate reader by adding 2 µL of the reaction mix to 10 mL of the Firefly 
Luciferase Assay Substrate. 
2.2.6 Cellular translation inhibition assay 
The translation inhibition assay in cells was performed using a pRLSV40 vector 
(Promega). For the bicistronic reporter assays, the CrPV plasmid was purchased from 
Addgene and the polio IRES plasmid was a kind gift from Dr. Mario Koster, HZI. The 
assay consists of four parts: i) transformation, ii) plasmid purification, iii) transfection 
and iv) cellular translation inhibition assay 
Transformation: Transformation was carried out to amplify the plasmid. This was 
done in competent E.coli xtBluc strain. The strain is maintained as a frozen culture 
at -80°C in cryo vials as 200 µL aliquots per vial. 
The vials were thawed on ice and 10 ng of the plasmid to be amplified was added, 
mixed gently and incubated on ice for 30 minutes. The bacteria were heated at 42°C 
for 2 minutes and then placed on ice immediately for 5 minutes. The bacteria were 
transferred then to a test tube with 800 µL of LB Broth and incubated at 37°C for 60 
minutes at 180 rpm. The culture was then transferred to Eppendorf tubes and 
centrifuged at 2000 g for ten minutes. The pellet was resuspended in 1 mL of 
LB Broth and 100 µL of this mix was plated on a LB-agar plate with ampicillin and 
incubated at 37°C overnight. 
The next day a single colony was picked using a sterile toothpick. The toothpick was 
then dropped into a test tube with 5 mL of LB Broth with ampicillin and incubated at 
37°C for 4 to 6 hours with shaking. At the end of the incubation period the bacterial 
culture was transferred to an one litre culture flask with 250 mL LB Broth and 250 µL 
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of 1 mg/mL ampicillin and incubated for 12 to 14 hours. Care was taken not to 
incubate them for more than 16 hours as this would lead to cell lysis. 
Plasmid purification: The plasmid purification was carried out using NucleoBond 
Plasmid purification kit. The overnight bacterial culture was collected in a 250 mL tube 
and centrifuged at 4000 xg for 15 minutes. The supernatant was discarded and the 
pellet was gently resuspended in 12 mL of Buffer S1 supplemented with RNase. To 
this 12 mL of Buffer S2 was added, mixed by inverting gently 6 to 8 times and 
incubated at room temperature for 3 minutes. Then 12 mL of Buffer S3 was added 
and inverted 6-8 times till an off white flocculate is formed. The mix was then 
incubated on ice for 5 minutes. The NucleoBond column was equilibrated with 5 mL of 
N2 Buffer. The flow through was discarded. The flocculate formed was filtered using a 
filter paper and the filtrate was collected. The filtrate was then loaded onto the column 
and the flow through was discarded. The column was washed with 32 mL of N3 
Buffer. The plasmid was eluted from the column using 15 mL of N3 Buffer. To this 
11 mL of room temperature isopropanol was added to precipitate the plasmid. The 
mix was then transferred to a 50 mL glass centrifuge tube and centrifuged at 
15000 x g for 45 minutes at 4°C. The supernatant was discarded and the pellet was 
dissolved in 1 mL of 70 % ethanol and centrifuged again at 15000 g for 10 minutes at 
4°C. The ethanol was then discarded and the pellet was dried at 37°C till the ethanol 
evaporated completely. The transparent pellet was then dissolved in 150 µL of 
nuclease free water. The quantity and purity of the plasmid was measured using a 
Nanodrop ND 1000. 
Transfection: Confluent KB-3-1 cells were trypsinised and cells were counted. The 
cells were resuspensed to get a final concentration of 1 X 105 cells/mL. 100 µL of this 
cell suspension was plated in each well of a 96-well plate. The following day, the 
medium was exchanged with 100 µL of fresh medium and the cells were incubated at 
37°C for one hour. In the meantime, 48 µg of the plasmid was mixed with 480 µL of 
DMEM and incubated for 5 minutes. To this mix 96 µL of 1 µg/mL polyethylenime 
(PEI) was added, mixed gently and incubated at room temperature for 15 minutes (or 
till the mixture becomes turbid). At the end of the incubation period of one hour, the 
96-well plate was removed from the incubator and 85 µL of the media was aspirated 
from each well. Then 6.5 µL of DNA-PEI mix was added to each well and incubated 
for 30 minutes in the incubator. Then 100 µL of fresh media was added and incubated 
for another 48 hours.  
Methods and Materials 
 
[37] 
 
Translation inhibition assay: The medium from the 96-well plate with the 
transfected cells was removed and fresh medium with the compounds in 
concentration range of 100-0.001 µg/mL was added to the cells. The plate was 
incubated for 3 hours. The cells were then lysed with 1 X Passive Lysis Buffer® 
(Promega). 5 µL of the cell lysate was mixed with 10 mL of the Luciferase Assay 
Buffer (Promega) and the luminescence was measured using a plate reader.  
2.2.7 Wash out assays 
Confluent A-431 cells were trypsinised and counted. 100 µL of 8 x 105 cells/mL cell 
suspension was plated in each well of a 96-well plate. The following day, the medium 
exchanged with fresh medium with varying concentrations of the compounds or 
methanol and incubated for either 6 or 24 hours. After the incubation period, the 
culture medium containing the compound was removed and washed gently with 
EBSS. Fresh culture medium without compounds or methanol was added and cells 
were cultured for 4 days. Cells that were continuously cultured in media with 
compounds or methanol were also cultured for 4 days. These cells served as 
comparison parameter. At the end of the incubation period the metabolic activity in 
each well was measured with an MTT assay and compared to cells that were 
continuously treated with compounds and methanol. 
2.2.8 Cell viability assay with CellTitreGlo® 
The cytotoxic effects of gephyronic acid and myriaporone 3/4 on primary (NHDF) and 
cancer cells (KB-3-1) were measured using the CellTitre-Glo® assay (Promega). The 
ATP level is taken as a parameter of cell viability. 10,000 cells/well were seeded in a 
96-well plate, grown over night and treated with serial dilutions of gephyronic acid or 
myriaporone 3/4. The final volume was maintained at 100 µL per well. Cells treated 
with methanol only served as control. After either 48 or 72 hours of incubation, the 
cells were mixed with 100 µL of CellTitre-Glo® and incubated at 37°C for 30 minutes. 
The plates were then left at room temperature in dark or wrapped in aluminium foil to 
normalise. The plate was shaken on a shaker for one minute and centrifuged shortly. 
The luminescence which correlates to the ATP levels in the cell were measured using 
a plate reader.  
2.2.9 Angiogenesis 
Inhibition of tube formation in vitro was tested using human umbilical endothelial cells 
(HUVECs) from LONZA. Frozen Matrigel (BD Biosciences) was thawed at -4°C 
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overnight, and after mixing it with an equal volume of cold EBM 2 medium (LONZA), 
35 µL aliquots were distributed in wells of a 96-well plate placed on ice. The plates 
were kept at 37°C then for 1 hour to let the Matrigel solidify. 25 µL of a suspension of 
HUVECs (8 x 105 cells/mL) that were harvested from a grown flask by trypsinization 
were given to each well, to which serial dilutions of the compounds were added. 
Plates were incubated at 37°C and 10 % CO2 overnight, and the tube formation was 
judged under the microscope with a 5x lens and documented using an attached CCD 
camera. 
2.2.10 Immunofluorescence  
Cell seeding: For fluorescence staining, cells were cultured on coverslips. First, a 
sterile coverslip with a diameter of 13 mm was placed into a well of a four well plate. 
PtK2 cells harvested by scrapping of a semi-confluent culture were diluted with 
medium 1:3. 750 µL of the diluted cell suspension was added to each well. and 
incubated overnight to ensure complete adherence. The compounds were added the 
following day. Care was taken that the concentration of the solvent MeOH and DMSO 
did not exceed 1%. The cells were incubated with the samples, for 4 to 6 hours 
depending on the experimental requirement at 37°C. 
Fixation: After the incubation, the cells were fixed with 750 µL of 3.7 % formalin for 
10 minutes The cells were washed once with sterile PBS and then treated for 5 min 
with 0.1% Triton X-100. In the treatment with formalin, the proteins are cross-linked 
and fixed in a gentle manner. Triton X-100 permeabilized the cells, allowing the 
antibodies / dyes to reach into the interior of the cells. After Triton X-100 treatment, 
the cells were also washed once with sterile PBS. 
Staining: Staining was done with appropriate antibodies. The primary antibody 
dilution varied with the antibody in use. Usually it was in the range of 1:50 to 1:500. 
The dilutions were prepared in PBS containing 10% FBS. DAPI was diluted to 1 ug / 
mL in PBS. The cells were incubated for 60 minutes with 250 µL of the primary 
antibody at 37°C and then washed with PBS twice. Then the cells were incubated with 
250 µL of secondary antibody tagged by a fluorochrome (Alexa Fluor 488 or Alexa 
Fluor 594). The secondary antibody was diluted to 1:500 with PBS containing 10 % 
FBS. The cells were washed twice with PBS. The coverslips were then removed from 
the wells, towel dried and embedded (with the cells down) onto a microscope slide 
with a drop of embedding medium (ProLong Antifade). 
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Creating the images: Images were taken with the CCD camera Axiocam mounted on 
the fluorescence microscope Axioplan (both from Zeiss). Neofluar objectives with 
magnifications of 63X and 100X were used for viewing. All the images were taken at 
63X magnification. 
2.2.11 SDS-PAGE 
SDS PAGE was performed using a commercial available gel from Bio Rad (4-20% 
Tris HCl gradient gel). Cells were lysed using MPER cell lysis buffer from Thermo 
Fisher Scientific supplemented with HALT protease/phosphatase inhibitor from Roche 
(1X). Protein was quantified using the Bradford method. 
40 µg of protein from the lysate was mixed with 5 µL of 4X SDS loading dye (Roth) 
and heated at 96°C for ten minutes. The sample was then loaded to the individual 
wells of the SDS gel placed in a vertical electrophoresis tank with SDS running buffer. 
A marker was also loaded to one well. Electrophoresis was carried out at 120 V for 
1.5 hours or till the loading front reached the end of the gel.  
2.2.12 Western blot 
Transfer: The proteins from the SDS PAGE gel were transferred to nitrocellulose 
membranes by a semi dry western blot method. The nitrocellulose membrane and 
Whatman filter paper was cut into 6 x 9 cm pieces. The membrane and 6 Whatman 
filter papers were then soaked in 1X blotting buffer with 20% methanol for at least ten 
minutes. Then membrane was placed onto 3 layers of Whatman filter paper. The gel 
was layered over the membrane and 3 more layers of Whatman paper were placed. 
The transfer was allowed to proceed at 120 V and 80 mA for 1 hour.  
Blocking and antibody incubation: The membrane was then removed from the 
transfer cassette and incubated in 5 % non-fat milk prepared in TBST buffer for 2 
hours at room temperature to block unspecific binding sites. The membrane was then 
washed shortly once with TBST. 10 µL of the stock antibody was added to 10 mL of 
TBST solution containing 1% BSA. This antibody mix was added to the blot and the 
blot was incubated at room temperature for 2 hours or at 4°C overnight. The primary 
antibody solution was removed, and washed 3 times with TBST. The blot was then 
incubated with 10 mL TBST containing 1% BSA and 0.5 µL of secondary antibody 
conjugated to HRP. The membrane  was washed with TBST again and prepared for 
detection. 
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Detection: Supersignal West Pico® chemiluminescence detection kit (Thermo Fisher 
Scientific) was used for detection. The membrane was incubated with a mix of 
Enhancer and Stable Peroxide Buffer in equal parts for 1 to 5 minutes. The membrane 
was then transferred to an X-ray cassette. In the dark room an X-ray film was placed 
in the cassette and exposed for 0.5 to 5 minutes. The film was developed using an 
Optimax developing machine. 
2.2.13 Silver staining 
Silver staining was carried out with a Pierce Silver Stain Kit from Thermo Fisher 
Scientific. The SDS gel was removed from the electrophoresis cassette and washed 
twice for 5 minutes in filtered Milipore water to remove the salts of the running buffer. 
Then the gel was incubated for 15 minutes in fixing solution made of 30% 
ethanol,10% acetic acid and 70 % water. The fixing process was repeated once again 
for 15 minutes. Then the gel was washed twice for 5 minutes each with 10% ethanol 
and twice with Milipore water for 5 minutes each. In the meanwhile the Sensitizer 
Working Solution was prepared (50 µL Sensitizer mixed with 25 mL water).The gel 
was incubated with the Sensitizer Working Solution for 1 minute, followed by 2 
washes with water for 1 minute each. The Stain Working Solution (0.5mL Enhancer 
mixed with 25 mL Stain) was prepared and the gel was incubated for 30 minutes. The 
Developer Working Solution (0.5 mL Enhancer with 25 mL Developer) was prepared. 
The gel was washed with ultrapure water twice for 20 seconds at each wash. The gel 
was then incubated with the Developer Working Solution 2 to 3 minutes until the 
bands appeared. Immediately after the bands appeared 5% acetic acid was added 
and incubated for 10 minutes. 
2.2.14 Pull down assay 
Preparation of cell lysates: KB-3-1 cells were cultured in three 75-cm2 flasks till they 
reached a 60-70% confluency. The culture medium was discarded and washed once 
with EBSS. The cells were then trypsinised, pooled, centrifuged and the cell pellet 
was collected. The cells were lysed with 1 mL of MPER lysis buffer supplemented with 
1X Halt protease-phosphotase inhibitor on ice for ten minutes. The lysate was 
centrifuged at 10,000g for ten minutes at 4°C. The supernatant was collected and the 
protein measurement measured using Bradford’s assay. The total protein 
concentration was maintained between 6-8 mg/mL. 
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Affinity capture of the target protein: The cell lysate was split into four Eppendorf 
tubes each of 200 µL in volume. 2 µL of methanol was added to tube 1, 2 µL of 
biotinylated gephyronic acid to tube 2 (1 mg/mL concentration), 1 µL of biotinylated 
gephyronic acid to tube 3 and 2 µL of gephyronic acid to tube 4.All the tubes were 
incubated on ice with mild shaking for 1 hour. Then 1 µL of gephyronic acid was 
added only to tube 3 and all tubes were incubated at 4°C for another 1 hour.  
At the end of one hour, the contents of the individual tubes were loaded to different 
1.5-mL Eppendorf tubes with 200 µL Dynabeads® M-280 Streptavidin beads from 
Invitrogen. The beads were washed 3 times with PBS before the lysates were added. 
The lysate-Dynabeads mix was incubated for 1 hour at room temperature with 
intermediate shaking. After one hour the Eppendorf tubes were centrifuged at 5000 
rpm for 2 minutes to sediment the streptavidin coated magnetic beads. The 
supernatant was discarded and the beads were washed 3-4 times with PBS to 
remove unbound and unspecifically bound proteins. The beads were then mixed with 
40 µL of 4X SDS loading buffer from Roth and heated at 96°C for ten minutes. The 
tubes were cooled on ice and centrifuged at 5000 rpm for 5 minutes. The collected 
supernatant contained the biotinylated proteins from the cell lysate and the target of 
gephyronic acid A.  
Detection: 20 µL of the heated loading dye with proteins were then loaded in the 
wells of 4-20% gradient SDS gel and electrophoresis was performed as mentioned 
above. The gel was then subjected to either silver staining or western blotting. 
2.2.15 DARTS 
Preparation of cell lysate: KB-3-1 cells were cultured to 70-80% confluency in a 
75-cm2 cell culture flask. The cells were trypsinised and centrifuged. The cell pellet 
was washed once with PBS and centrifuged again. The pellet was resuspended in 
800 µL of MPER lysis buffer (Pierce) in a 1.5-mL Eppendorf tube and subjected to cell 
lysis on ice for ten minutes. After ten minutes, the tubes were centrifuged, the 
supernatant was collected and the protein content measured using Bradford’s assay. 
Digestion with pronase: 40 µg of the protein lysate was incubated with the 
compounds or methanol for 2 hours at room temperature. The mixture was digested 
with 20 ng of Pronase (Roche) at 37°C for 30 min. The digestion was stopped by 
heating with 5 µL 4X loading dye (Roth). 
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Detection: The sample was separated by SDS-PAGE (4-20% Tris-HCl gels) and was 
either subjected to Coomassie staining and viewed or transferred onto a nitrocellulose 
membrane. The membrane was then subjected to western blotting with the required 
antibodies and viewed by the chemiluminescene as mention in section 2.2.12. 
2.2.16 Overexpression assay 
Translation inhibition assay was performed by using the Flexi Rabbit Reticulocyte 
Lysate system (Promega) supplemented with either with an eEF2K expressed lysate 
or empty vector lysate (Novobios). Briefly, 500 ng of luciferase mRNA was combined 
with 17.5 µL of rabbit reticulocyte lysate, 0.25 µL of 1 mM –Met and –Leu amino acid 
mixtures, 0.7 µL of 2.5 M KCl, 10 U RNasin, 3.3 µL of nuclease free water, 25 µL of 
either eEF2K or empty vector lysate (containing 100 µg/mL of total protein) and 1 µL 
of myriaporone to give a final concentration ranging from 100-0.001 µg/mL. The 
reaction mixtures were incubated at 30°C for 90 minutes. Luminescence was 
measured by mixing 2 µL of the mixture with 10 mL of the Luciferase Assay Substrate 
(Promega). 
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3 Results 
3.1 Establishment of polyketides as translation inhibitors 
3.1.1 Cytotoxicity profiling with mammalian cells 
To test the cytotoxicity of the four polyketides that were investigated during this study 
in higher eukaryotes different mammalian cell lines were used, including the human 
cancer cell lines KB-3-1, PC-3, A-459, and A-431, and transformed cells from mouse 
and potoroo, L-929 and PtK2, respectively. The compounds were incubated with the 
cells in serial dilutions in micro-titre plates for a period of 5 days. The influence on the 
metabolic activity of the cells was measured by an MTT assay. As can be seen from 
Table 3.1 all the four compounds inhibited the viability of the cells in nanomolar 
ranges. 
Table 3.1: Cytotoxicity of the polyketides in mammalian cells 
The values represent the IC50 of the each compound measured by an MTT assay. 
Cell line 
Gephyronic acid 
(nM) 
Myriaporone 3/4 
(nM) 
Des-epoxy 
tedanolide (nM) 
Aetheramide B 
(nM) 
L-929 100 8 1.6 40 
KB-3-1 14 4 0.6 30 
A-431 14 11 1.2 - 
A-549 8 10 - 35 
PC-3 6 8 5 15 
PtK2 32 10.5 1.8 30 
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3.1.2 Antimicrobial activity profiling with prokaryotes and fungi 
All four polyketides were examined for their biological activity towards a broad 
spectrum of microorganisms. By default, eight microorganisms (bacteria and fungi) 
were tested. Ciprofloxacin, a known antibiotic, and nystatin, a known antifungal agent 
were used as positive controls and also as a comparison standard. The profiling was 
carried out using zone of inhibition assays as explained in the methods section. The 
results are depicted in Table 3.2. 
Table 3.2: Results of agar diffusion assays with microorganisms 
Diameter of zone of inhibition is given in mm. 
Test organism Gephy-
ronic acid 
Myria-
porone 
3/4  
Des-epoxy 
tedanolide 
Aetheramide 
B 
Cipro-
floxacin 
Nystatin 
Gram-negative 
Bacteria 
      
E. coli tolC < 7 < 7 < 7 < 7 16  < 7 
Klebsiella 
pneumoniae 
< 7 < 7 < 7 < 7 13  < 7 
Pseudomonas 
aeruginosa 
< 7 < 7 < 7 < 7 27 < 7 
Gram-positive 
Bacteria 
      
Staphylococcus 
aureus 
< 7 < 7 < 7 < 7 31 < 7 
Micrococcus 
luteus 
< 7 < 7 < 7 < 7 40 < 7 
Yeasts 
      
Candida 
albicans 
27 20 16 10 < 7 19 
Hansenula 
anomala 
30  16 < 7 < 7 25 
Saccharomyces 
cerevisiae 
21 15 < 7 < 7 < 7 20 
 
Results 
 
[45] 
 
3.1.3 Translation inhibition in vitro 
Three of the four polyketides (gephyronic acid, myriaporone 3/4, des-epoxy 
tedanolide) had been shown to inhibit translation previously. To confirm these findings 
and to determine the IC50 values in translation inhibition, in vitro translation assays 
were performed. A rabbit reticulocyte lysate was supplemented with firefly luciferase 
mRNA and amino acids and incubated with different concentrations of the test 
compounds. The resulting luminescence which is directly proportional to the 
translation of luciferase mRNA was measured after 90 minutes of incubation at 30°C. 
The readout showed an inhibition of translation by all compounds. The IC50 values 
were 0.07 µM for gephyronic acid (Fig. 3.1A), 0.4 µM for myriaporone 3/4 (Fig. 3.1B), 
0.01 µM for des-epoxy tedanolide (Fig. 3.1C) and 1.1 µM for aetheramide B (Fig. 
3.1D). Cycloheximide, a known eukaryotic translation inhibitor was used as a positive 
control. It showed an IC50 of 1.5 µM. 
 
 
 
 
 
 
 
Figure 3.1:Translation inhibition in rabbit reticulocyte lysates 
Translation inhibition in rabbit reticulocyte lysates by gephyronic acid (A), myriaporone 3/4 (B), 
des-epoxy tedanolide (C) and aetheramide B (D). Cycloheximide was used as a positive 
control (A). 
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3.1.4 Translation inhibition in cells 
To prove the inhibition of de novo protein synthesis in cells, KB-3-1 cells were 
transfected with a pRLSV40 vector coding for Renilla luciferase. 48 hours after 
transfection, cells were treated with varying concentrations of either gephyronic acid, 
myriaporone 3/4, des-epoxy tedanolide, aetheramide B or cycloheximide for 4 hours. 
Cycloheximide inhibited the cellular translation with an IC50 of 50 nM. Gephyronic acid 
showed an IC50 of 30 nM, myriaporone 3/4 of 100 nM, des-epoxy tedanolide of 0.2 nM 
and aetheramide had an IC50 of 700 nM (Fig. 3.2). These results were consistent with 
the in vitro data. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Translation inhibition in KB-3-1 cells 
Translation inhibition in KB-3-1 cells transiently transfected with pRLSV40 vector by 
gephyronic acid (A, black bars), myriaporone 3/4 (B), des-epoxy tedanolide (C) and 
aetheramide B (D). Cycloheximide was used as a positive control (A, white bars). 
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3.2 Identification of the mode action of gephyronic acid 
The results reported in the previous section showed that all the four compounds 
inhibited protein biosynthesis. This could be proven by assays in vitro and in cell 
cultures. In the following the mode of action of each compound is described in detail. 
3.2.1 Induction of apoptosis 
To test for the induction of apoptosis by gephyronic acid, A-431 skin cancer cells were 
treated with 50 nM of the compound for 3, 6, 12 and 24 hours and labelled by PI and 
FITC-Annexin V. An ongoing apoptosis in the cells was measured by flow cytometry 
(FACS). Methanol treated cells were used as control. Fig. 3.3 shows the distribution of 
the fluorescent cells in 4 quadrants. Cells in quadrant 4 show early apoptosis, and 
cells in quadrant 2 late apoptosis. It can be seen that within 3 hours of treatment with 
gephyronic acid, a significant higher percentage of cells (in total 11 %) underwent 
apoptosis as compared to the control (4.4 %). After 24 hours the percentage has 
increased to 20 %. 
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Figure 3.3: Induction of apoptosis 
FACS analysis of A-431 cells at different time points showed an increase in apoptotic cells 
when incubated with gephyronic acid. After 24 hours 20.9% of the cells treated with the 
translation inhibitor (50 nM) had undergone apoptosis compared to 4.5 % of the cells treated 
with methanol only. 
 
3.2.2 Reversibility of the cytotoxic effect induced by gephyronic acid  
To test the reversibility of the cytotoxic effect of gephyronic acid, A-431 cells were 
treated with the inhibitor for 6 or 24 hours. At the end of the incubation period, the 
culture media of a part of the cells were removed and replaced by fresh media. The 
cells were cultured for further 4 days then. An MTT assay was performed to measure 
cell viability. As can be seen from Fig. 3.4, the IC50 of the cells treated for 6 hours only 
was higher  than of the control cells which were continuously treated with gephyronic 
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acid. After 24 hours the cytotoxic effects were no longer reversible. The IC50 value of 
washed and non-washed cells differed only slightly.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Reversibility of the cytotoxic effect 
Human epidermoid cancer cells A-431 were incubated with serial dilutions of the compound for 
6 (A) or 24 (B) hours, washed with EBSS, and grown for further 4 days. Reference cells were 
continuously incubated with gephyronic acid. Cell viability was measured with an MTT test.  
 
3.2.3 Toxicity of gephyronic acid in primary cells 
Translation inhibitors might have differences in cytotoxicity in transformed cells when 
compared to the primary, healthy cells. To test if this was true for gephyronic acid, 
cancerous KB-3-1 cells and primary dermal fibroblasts (NHDF) were treated with 
varying concentrations of gephyronic acid and analysed for their ATP content as a 
parameter of viability. After 72 hours of incubation, the IC50 was 14 nM with KB-3-1 
cells compared to 8 µM with NHDF (Fig. 3.5B). After 48 hours the IC50 was 0.004 µM 
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with KB-3-1 cells and 2 µM for NHDF cells. (Fig. 3.5A). The results showed that the 
cancer cells were at least 80 fold more sensitive to gephyronic acid than normal cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Comparison of the toxicity of gephyronic acid to healthy and cancer cells 
ATP level were measured as a parameter of viability with KB-3-1 and NHDF cells. Gephyronic 
acid induced less cytotoxic effects in primary NHDF cells. 
 
3.2.4 In vitro tube formation as a model for angiogenesis 
Translation inhibitors like rapamycin, have been shown to inhibit angiogenesis, i.e. 
translation inhibitors are anti-cancer agents (Del Bufalo et al., 2006). To test the 
potential of gephyronic acid in that respect an in vitro tube formation assay was used. 
HUVECs were seeded on Matrigel®, which mimics the angiogenesis in vivo. While 
the control cells formed vessel like structures, cells treated with gephyronic acid did 
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not form tubes (Fig. 3.6). This effect was dose dependant. The minimal inhibition 
concentration (MIC) was observed to be 0.3 µM. 
 
 
 
 
 
 
0 
 
 
 
 
 
 
Figure 3.6: Gephyronic acid inhibits tube formation in vitro 
HUVECs plated on Matrigel were treated with various concentrations of gephyronic acid. 
Gephyronic acid inhibited angiogenesis in a dose dependant manner with an MIC of 0.3 µM. 
 
3.2.5 Comparison of inhibition in eukaryotic and prokaryotic 
translation systems 
Gephyronic acid inhibits translation in the rabbit reticulocyte lysate system. The next 
assessment was to analyse if gephyronic acid was a pan eukaryotic translation 
inhibitor. Therefore wheat germ lysate supplemented with luciferase mRNA and amino 
acids was employed. The mixture treated with various concentrations of gephyronic 
acid was incubated at 37ºC for 60 minutes and the luminescence was measured. As 
can be seen from Fig. 3.7A, gephyronic acid inhibited translation in wheat germ lysate 
3.33 µM 1.1 µM 
0.3 µM Methanol 
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in a dose dependant manner showing that gephyronic acid is a general eukaryotic 
translation inhibitor. However, when gephyronic acid was tested with E. coli lysate 
supplemented with luciferase mRNA, there was no inhibition of luminescence as seen 
from Fig. 3.7B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Gephyronic acid does not inhibit prokaryotic translation 
Wheat germ lysate (A) and E.coli cell lysate (B) were incubated with luciferase mRNA, amino 
acids and gephyronic acid at various concentrations. The luminescence plotted with respect to 
control shows a dose dependent reduction in translation only in wheat germ lysate. 
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3.2.6 Determining the phase of translation inhibition 
To determine the phase of translation inhibition induced by gephyronic acid, a 
bicistronic system which consisted of firefly luciferase translated by a cap-dependant 
system and Renilla luciferase translated by CrPV or polio IRES system was used 
(Fig.  3.8).  
 
 
 
 
Figure 3.8: Structure of the bicistronic vector 
The bicistronic vector consists of two open reading frames (ORF). The first ORF coding for the 
firefly luciferase is translated via the 5’ cap dependant system and the Renilla luciferase is 
translated by the IRES system. 
 
KB 3-1 cells transfected with the CrPV bicistronic vector were treated with gephyronic 
acid, cycloheximide and pateamine A at concentrations ranging from 1.0 - 0.01 µM for 
3 hours. The luminescence generated from the two luciferases was measured. 
Cycloheximide, which stalls the elongation phase (Schneider-Poetsch et al., 2010), 
inhibited the translation of Renilla and firefly luciferase reporter systems equally (Fig. 
3.9). On the other hand, pateamine A which inhibits the initiation phase of translation 
(Low et al., 2005) inhibited only the luminescence from the firefly luciferase. The 
Renilla luciferase encoded by the CrPV IRES was not inhibited. Gephyronic acid also 
inhibited the luminescence only from the firefly luciferase similar to pateamine A. This 
suggests that gephyronic acid inhibits the initiation phase. 
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Figure 3.9: Gephyronic acid does not inhibit CrPV IRES 
A bicistronic vector was used to determine the phase of translation inhibition. Gephyronic acid 
(panel A) inhibits only the cap-dependant translation system in a similar way as pateamine A 
(panel B), while cycloheximide (panel C) inhibits both systems.  
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3.2.7 Effect of gephyronic acid on the eIF4 complex 
From the previous section it was clear that gephyronic acid targeted the initiation 
phase. To analyse if gephyronic acid targets the eIF4 complex within the initiation 
phase of translation a bicistronic vector consisting of firefly luciferase translated by the 
cap-dependant system and Renilla luciferase translation polio IRES dependant 
system was used (Fig. 3.8). Polio IRES does not require eIF4E and eIF4G to initiate 
translation as mentioned in section 1.2.6. If gephyronic acid inhibits the translation of 
the Renilla luciferase it suggests that gephyronic acid does not target eIf4E or eIF4G. 
To determine the phase of translation inhibition induced by gephyronic acid, KB-3-1 
cells were transfected with the polio IRES bicistronic vector. 48 hours after 
transfection the cells were treated with gephyronic acid, cycloheximide and 
pateamine A. Cycloheximide and patemine A were used as controls. Pateamine A 
inhibits translation initiation by interfering with eIF4A whereas cycloheximide inhibits 
the elongation phase and thus requires eIF4G and eIF4E. As a result, both 
pateamine A and cycloheximide inhibit the translation of the Renilla luciferase similar 
to the firefly luciferase (Fig 3.10). Gephyronic acid inhibits the translation of both the 
firefly and the Renilla luciferase equally as represented by the inhibition of the 
luminescence from both the luciferases. This suggests that the target of gephyronic 
acid does not involve eIF4G and eIF4E. 
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Figure 3.10: Gephyronic acid inhibits the translation by polio IRES 
Gephyronic acid similar to pateamine A and cycloheximide, inhibits the polio IRES translation 
(A, white bars) and the cap-dependant translation system. 
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3.2.8 Elucidating the target of gephyronic acid 
With the knowledge that gephyronic acid inhibits translation initiation, a fitness based 
chemo-genetics approach with Saccharomyces cerevisiae mutants was used to 
identify the possible target. The yeast mutants were obtained from EUROSCARF 
(Giaever et al., 2002; Parsons et al., 2006). Viable mutants involved in translation 
elongation and initiation phase were used for this assay. Treating these mutants with 
gephyronic acid would show an increased sensitivity when gephyronic acid binds to a 
target that is closely related to the knocked out pathway in the mutant. The screening 
results with gephyronic acid showed that most of the mutants had the same sensitivity 
as the wild type. As seen from Table 3.3 only the eIF2B mutant was clearly more 
sensitive. This suggests that the target of gephyronic acid lies in the eIF2 complex. 
Table 3.3: Chemical-genetics with yeast mutants 
 
 
 
 
Mutant name Gene knocked out Inhibition zone  
(Diameter in mm) 
YJL138C eIF4A 20 
YGL049C eIF4G 19 
YKL204W eIF4E associated ptn 20 
YKL081W EF-1gamma 20 
YKR026C eIF2B alpha 28 
YLR199C Protein involved in 20S 
proteasome assembly 
15 
YAL035W eIF5B 20 
WT - 21 
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3.2.9 Elucidating the target of gephyronic acid with DARTS approach. 
To identify the direct target of gephyronic acid a drug affinity responsive target stability 
(DARTS) approach was used. The basis of this method is that binding of a ligand to a 
protein target reduces the susceptibility of the protein to protease digestion due to a 
stabilization of the protein’s folded state (Lomenick et al., 2009). KB-3-1 cell lysates 
were incubated with various concentrations of gephyronic acid for 2 hours and 
subjected to pronase digestion for 30 minutes at 37°C. Cycloheximide treated cell 
lysate was used as a control. Cell lysate treated with only methanol and then 
subjected to digestion were used as a control. The digestion was stopped by heating 
with SDS loading for ten minutes at 96ºC. An SDS PAGE was performed with the 
samples. The protein bands were stained with Coomassie Brilliant Blue. Protection of 
a band at ~36 kDa was noticed (Fig. 3.11.) This protection was concentration 
dependent. The protein from the eIF2 complex with a molecular weight of 36 KDa is 
eIF2 alpha.  
 
 
 
 
 
 
 
 
Figure 3.11: DARTS approach with gephyronic acid 
KB-3-1 cell lysates treated with varying concentration of gephyronic acid were subjected to a 
DARTS protocol with pronase. After SDS-PAGE the gel was stained with Coomasse Brilliant 
Blue. Lysate treated with cycloheximide served as negative control. Gephyronic acid protected 
a protein band at 36 kDa in a dose dependent manner. Cycloheximide did not. 
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Hence the experiment was repeated with the same controls as above followed by a 
western blot using an anti eIF2α antibody. The blot was also re-probed with an anti-
GAPDH antibody to serve as a loading control for the proteins. As can be seen from 
Fig. 3.12, gephyronic acid treated cells showed a concentration dependent protection 
of eIF2α. Cycloheximide failed to protect eIF2α from pronase digestion even at its 
highest concentration (250 µM). 
Pronase + - + + + 
Gephyronic acid - + 1µM 100nM - 
Cycloheximide - - - - 
250 
µM 
 
 
 
 
 
Figure 3.12: DARTS approach with gephyronic acid 
KB-3-1 cell lysates treated with varying concentration of gephyronic acid were subjected to 
digestion with pronase. Lysates treated with cycloheximide served as negative control. The 
lysates were then subjected to western blot with an anti-eIF2α antibody. Gephyronic acid 
protected eIF2α in a dose dependant manner. GAPDH was used as a loading control. 
 
 
3.2.10 Target fishing with biotinylated gephyronic acid 
In order to fish the target protein biotinylated gephyronic acid was used with a biotin 
attached to the hydroxyl group at C3 (Fig. 3.13). 
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Figure 3.13: Structure of biotinylated gephyronic acid. 
 
To test if the biotinylated gephyronic acid is as active as the parent compound, KB-3-1 
cells were treated with biotinylated gephyronic acid for 5 days and an MTT assay was 
performed to assess the viability (Fig. 3.14A). The IC50 of the compound was 45 nM, 
i.e. it is almost as effective as gephyronic acid. To test that the biotinylation did not 
alter the properties of gephyronic acid, biotinylated gephyronic acid was also tested 
for its translation inhibition. As seen from Fig. 3.14B, the biotinylated gephyronic acid 
inhibited translation almost to the same degree as gephyronic acid. The IC50 was 
0.4 µM. 
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Figure 3.14: Biotinylated gephyronic acid has parental properties 
Biotinylated gephyronic acid was almost as cytotoxic as the parent compound with an IC50 of 
45 nM (a).  Biotinylated gephyronic acid incubated with rabbit reticulocyte lysate supplemented 
with mRNA and amino acids inhibited translation (b). 
 
3.2.11 Immunofluorescence investigations with biotinylated gephyronic 
acid 
To confirm the target of gephyronic acid, PtK2 cells were treated with biotinylated 
gephyronic acid for 3 hours. Then they were stained with Alexa Fluor 488 labelled 
streptavidin and an anti eIF2α antibody from mouse which was made visible by a. 
secondary anti mouse Alexa Fluor 594 antibody. As a result, biotinylated gephyronic 
acid was stained green, as was the cellular biotin, and eIF2α was stained red. 
Gephyronic acid treated cells served as control. Cells treated with gephyronic acid 
A) 
B) 
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also showed green fluorescence due to the affinity of streptavidin to mitochondrial 
biotin, but in cells treated with biotinylated gephyronic acid there is co-localisation of 
eIF2α and biotin (Fig. 3.15) whereas in the cells treated with gephyronic acid there is 
no co-localisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Co-localisation studies with biotinylated gephyronic acid 
PtK2 cells were treated with 50 nM of gephyronic acid or biotinylated gephyronic acid for 3 
hours and stained using streptavidin (labelled green), which binds to biotin, and an anti-
eIF2αα antibody (red). Biotinylated gephyronic acid co-localises with eIF2α. Scale bar: 50 µm. 
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3.2.12 Pull down assay with biotinylated gephyronic acid 
To prove further that eIF2α is the target of gephyronic acid, a pull down assay was 
performed with the biotinylated gephyronic acid. A KB-3-1 cell lysate was treated with 
biotinylated gephyronic acid. A lysate treated with gephyronic acid served as negative 
control. One batch of the lysates was incubated with biotinylated gephyronic acid for 
one hour and then with gephyronic acid for the next hours to show competitive 
binding. Then the lysates were incubated with streptavidin magnetic beads. The 
beads were washed to remove unspecifically bound proteins and heated with 4X SDS 
denaturing loading dye at 96ºC for ten minutes. Proteins were separated by SDS 
PAGE. The gel was then subjected to silver staining. In line with previous results, a 
band at 36 kDa was observed in the lanes of lysates treated with the biotinylated 
gephyronic acid and a fainter one in the lysate that were treated with both compounds 
(Fig. 3.16).  
 
 
 
 
 
 
 
 
 
Figure 3.16: Pull down assay with biotinylated gephyronic acid. 
KB-3-1 cell lysates were incubated with methanol (lane 1), gephyronic acid (lane 2), 
biotinylated gephyronic acid (lane 3) or a mixture of biotinylated gephyronic acid and native 
gephyronic acid (lane 4) and the targets pulled down using streptavidin beads. The eluates 
were analysed by SDS-PAGE followed by silver staining. The lysate treated with biotinylated 
gephyronic acid or the mixture showed an additional band at 36 kDa. 
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The same experimental setup was repeated and the gel was subjected to western blot 
using an anti eIF2α antibody. As can be seen from Fig. 3.17, lane 2 (treated with 
biotinylated gephyronic acid) and lane 3 (treated with biotinylated gephyronic acid and 
gephyronic acid) show a band whereas it is almost absent from the lane 1 and 4 
which was treated with methanol or with gephyronic acid. The membrane was also 
probed with anti-pyruvate carboxylase (PC) antibody which is present in the 
mitochondria. PC is a biotin containing protein which also binds to streptavidin and is 
also fished. Thus, PC could serve as a loading control for the assay. 
 
 
 
 
 
 
 
Figure 3.17: Western blot with pulled down lysates 
KB-3-1 cell lysates were incubated with methanol (lane 1), biotinylated gephyronic acid (lane 
2), a mixture of biotinylated gephyronic acid and gephyronic acid (lane 3) or gephyronic acid 
(lane 4). The targets were pulled down using a streptavidin column. The eluates were 
analysed by SDS-PAGE followed by western blotting with anti-eIF2α antibody. PC served as 
loading control. The lysate treated with biotinylated gephyronic acid and the mixture showed a 
band of eIF2α whereas the lysates treated with methanol or gephyronic acid did not show a 
band. PC is equally present in all lanes (MW = 129 kDa). 
 
3.2.13 Predicting the binding pocket of gephyronic acid in eIF2α 
To locate the binding pocket of gephyronic acid in eIF2α, docking calculations were 
performed using the Vina program. Since the crystal structure of the target region for 
eIF2α specific kinases is known, the coordinates deposited in the Protein Data Bank 
with the accession number 1Q46 could be used for the calculations (Dhaliwal and 
Hoffman, 2003). An inactive isomer of gephyronic acid (synthetic) reported by Anderl 
et al. (2011) was also used for the docking calculations (Fig. 3.18)  
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Figure 3.18: Structure of gephyronic acid isomer used for docking calculations 
 
The PODRG server was used to get the coordinates and charges (Schuttelkopf and 
van Aalten, 2004). The known 3D chiral centres were checked. For the inactive 
isomer the chiral centres were inverted using Jmol and the charges reassigned on the 
PRODRG server. During a first run the residues involved in the interaction were 
determined. In a second run torsion angle changes in all related side chains were 
allowed. The calculations were performed using the known 3D structure of gephyronic 
acid and the related stereo isomer. The results showed that the aliphatic ends of 
gephyronic acid and its inactive isomer were bound to Ala 130 and Ala 140, the 
carboxylic ends to Glu 15 and Asp 17. The natural gephyronic acid was additionally 
bound to Tyr 39, which increases the binding energy from 26 to 29 kJ/mol. As seen in 
Fig. 3.19, this is obviously due to the geometry related to the epoxide group.  
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Figure 3.19: The binding pocket of gephyronic acid 
(a) The calculated binding pocket of gephyronic acid , (b) the stereo isomer shows much lower 
affinity. 
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3.3 Identification of mode action of myriaporone 3/4  
As described in Sections 3.1.3 and 3.1.4 myriaporone 3/4 inhibited translation both in 
vitro and in cells in nanomolar ranges, but the mechanism of translation inhibition and 
the target protein had still to be elucidated. 
3.3.1 Analysis of myriaporone cytotoxicity by FACS 
To test the kinetics of cell death induction by myriaporone 3/4, A-431 cells were 
treated with 90 nM of the polyketide for 3, 6, and 24 hours. The induction of apoptosis 
in the cells was measured by flow cytometry (FACS). Methanol treated cells were 
used as control. From Fig. 3.20 it can be seen that within 6 hours of treatment with 
myriaporone 3/4, a significant percentage of cells (14 %) underwent apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: FACS  analysis of apoptotic effects in A-431 cells 
Myriaporone 3/4 induced a time dependant apoptosis as can be seen by the increasing 
numbers of cells in quadrant 4 and 2. 
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3.3.2 Activity of myriaporone 3/4 in primary cells 
Though myriaporone 3/4 was active in nanomolar ranges in the cancerous cell lines, 
the effect could be less pronounced in primary cells. Therefore cells of the tumour cell 
line KB-3-1 and primary fibroblasts (NHDF) were incubated with increasing 
concentrations of myriaporone 3/4 for 48 and 72 hours. As a parameter of viability, the 
cells were assayed for their ATP content. While the viability of KB-3-1 cells was 
strongly reduced resulting in an IC50 of 0.2 and 0.6 µM after 48 and 72 hours, 
respectively, the NHDF cells were much less affected. Even after 72 hours the highest 
concentration applied (20 µM) showed only 20 % reduction in cell viability (Fig. 3.21). 
As a result the primary cells were around 300 times less sensitive to myriaporone 3/4 
than the cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Cytotoxicity of myriaporone 3/4 to primary and cancer cells 
Myriaporone 3/4 showed less cytotoxic effect to primary NHDF cells (white bars) compared to 
cancerous KB-3-1 cells (black bars) after an incubation of 48 (A) and 72 hours (B). 
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3.3.3 Influence of myriaporone 3/4 on angiogenesis 
As mentioned earlier translation inhibitors have been shown to inhibit angiogenesis. 
To test if myriaporone could inhibit angiogenesis, an in vitro tube formation model was 
used. HUVECs plated in Matrigel® were treated with myriaporone 3/4 in a 
concentration range of 2.0 – 0.002 µM. Myriaporone inhibited the tube formation with 
an MIC of 0.04 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Myriaporone 3/4 inhibits tube formation by HUVECs 
The cells were treated with various concentrations of myriaporone. Panel A (2 µM of 
myriaporone 3/4) and panel B (80 nM of myriaporone 3/4) are representative figures. Panel C 
shows HUVECs treated with 200 nM suramin as a positive control. Cells in panel D were 
treated with the vehicle methanol only. Scale bar: 50 µm. 
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3.3.4 Comparison of the effects of myriaporone 3/4 on eukaryotic and 
prokaryotic translation 
To analyse if myriaporone 3/4 is a general eukaryotic translation inhibitor, a wheat 
germ lysate supplemented with luciferase mRNA and amino acids was employed. The 
mixture treated with various concentration of myriaporone 3/4 was incubated at 37ºC 
for 60 minutes and the luminescence was measured. Myriaporone 3/4 inhibited the 
translation in the wheat germ lysate (Fig. 3.23 A) as already seen with the reticulocyte 
lysate. As myriaporone 3/4 was inactive in prokaryotes as seen in Section 3.1. It 
should not inhibit the prokaryotic translation system. To test this, E. coli cell lysate was 
supplemented with luciferase mRNA and amino acid and incubated with different 
concentrations of myriaporone 3/4 at 30ºC. The resulting luminescence was 
measured after two hours. As expected myriaporone 3/4 did not inhibit the translation 
of the E. coli system (Fig. 3.23 B).  
 
 
 
 
 
 
 
Figure 3.23: Myriaporone 3/4 does not inhibit prokaryotic translation 
Wheat germ lysates (A) and E. coli cell lysates (B) were incubated with luciferase mRNA, 
amino acids and myriaporone 3/4 in various concentrations. The luminescence plotted with 
respect to control shows a dose dependent reduction in translation only in the wheat germ 
lysate. 
 
 
 
 
Wheat germ lysate
Concentration (µM)
100 10 1 0.1 0.01
Lu
m
in
e
sc
e
n
ce
 
(%
 
co
n
tro
l)
0
20
40
60
80
100
120
Myriaporone 3/4 
E.coli cell lysate
Concentration (µM)
100 10 1 0.1 0.01
Lu
m
in
e
sc
e
n
ce
 
(%
 
co
n
tro
l)
0
20
40
60
80
100
120
140
Myriaporone 3/4
A) B) 
Results 
 
[71] 
 
3.3.5 Effect of myriaporone 3/4 on translation initiation 
From the translation inhibition assays it was seen that myriaporone 3/4 inhibited 
translation. To determine if myriaporone 3/4 disrupts translation initiation the 
bicistronic system as mentioned in Section 3.2.6 which consisted of firefly luciferase 
translated by a cap-dependant and Renilla luciferase translated by CrPV IRES 
systems was used. For the CrPV IRES all the initiation factors are dispensable. If the 
translation is nevertheless stopped, it implies that myriaporone 3/4 does not target the 
initiation phase. KB-3-1 cells transfected with the above vector were treated with 
myriaporone 3/4, pateamine A and cycloheximide at concentrations ranging from 1.0 - 
0.01 µM for 3 hours. The luminescence generated from the two luciferases was 
measured. Myriaporone 3/4 inhibited the translation of Renilla and firefly luciferase 
from the reporter systems equally like cycloheximide. Pateamine A inhibited only the 
cap dependant system as it inhibits the initiation phase. From this experiment, it is 
clear that myriaporone is rather an inhibitor of the elongation phase. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Myriaporone inhibits CrPV IRES 
Myriaporone 3/4 (A) like cycloheximide (B) inhibits the translation of the Renilla luciferase 
coded by the CrPV IRES (white bars) similar to the cap-dependant translation of the firefly 
luciferase (black bars). Pateamine A which targets the initiation inhibits only the 
cap-dependant translation. 
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3.3.6 Influence of myriaporone 3/4 on eIF4 complex  
Though myriaporone 3/4 inhibited translation of CrPV IRES, it could have a target 
within the eIF4 complex. To determine if myriaporone 3/4 disrupts the eIF4 complex, 
the bicistronic system as mentioned in Section 3.2.6 which consisted of firefly 
luciferase translated by a cap-dependant system and Renilla luciferase translated by 
polio IRES systems was used. For the polio IRES only eIF4G and eIF4E are 
dispensable. If the translation is nevertheless stopped, it cannot be due to interference 
with the eIF4 complex. KB 3-1 cells transfected with the above vectors were treated 
with myriaporone 3/4, pateamine A and cycloheximide at concentrations ranging from 
1 0 - 0.01 µM for 3 hours. The luminescence generated from the two luciferases was 
measured. Myriaporone 3/4 like cycloheximide and pateamine A (targets eIF4A) 
inhibited the translation of Renilla and firefly luciferase from the reporter systems 
equally. This suggests that myriaporone does not target eIF4E or eIF4G. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: Myriaporone 3/4 inhibits polio IRES dependant translation 
Myriaporone 3/4 (A) like cycloheximide (B) and pateamine A (C) inhibits the translation of the 
Renilla luciferase coded by the polio IRES (white bars) similar to the cap-dependant translation 
of the firefly luciferase (black bars).  
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3.3.7 Chemo-genetic interaction screening with myriaporone 3/4  
Since myriaporone 3/4 did not target the initiation phase it was hypothesised that it 
inhibits translation in the elongation phase. To test this further, a fitness based chemo-
genetics approach with yeast mutants was used. Viable knock out mutants of genes 
involved in translation elongation and initiation phase were used. The chemical-
genetic interaction was tested using an agar diffusion assay. Paper discs soaked with 
20 µg of myriaporone 3/4 were placed on YPD agar plates, which were inoculated 
with the mutant of interest. As expected, mutants with relation to initiation factors did 
not show an increased sensitivity. The elongation factor eEF1γ mutant also failed to 
show any change in the sensitivity compared to the WT which suggested that eEF1 
was also not influenced by myriaporone 3/4 (Table 3.4). 
Table 3.4: Results of a chemo-genetic interaction screening with yeast mutants 
 
 
 
Mutant name Gene knocked out Inhibition zone (mm) 
YJL138C eIF4A 15 
YGL049C eIF4G 15 
YKL204W eIF4E associated ptn 14 
YKL081W EF-1gamma 13 
YKR026C eIF2B alpha 14 
YLR199C Ptn involved in 20S 
proteasome assembly 
15 
YAL035W eIF5B 17 
WT - 15 
Results 
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3.3.8 Influence of myriaporone 3/4 on the phosphorylation of eEF2 
Myriaporone 3/4 did not affect any of the mutants in the yeast screening. Also from 
Section 3.3.5 it is clear that myriaporone does not target the initiation phase. 
Therefore it was assumed that myriaporone 3/4 could target the elongation phase. 
The elongation phase regulation is achieved by altering the phosphorylation state of 
eEF2. However, the eEF2 mutant is not viable in yeast. So the phosphorylation state 
of eEF2 was tested in mammalian cells. KB-3-1 cells cultured on coverslips in a four 
well plate were treated with 50 nM of myriaporone 3/4 for 4 hours. Cells treated with 
methanol served as control. The cells were then fixed and stained with 
anti-phosphorylated-eEF2 antibody. As can be seen from the Fig. 3.26, cells treated 
with myriaporone 3/4 show increased levels of phosphorylation as indicated by the 
increased green fluorescence. 
 
 
 
 
 
Figure 3.26: Myriaporone 3/4 induces phosphorylation of eEF2 
KB-3-1 cells were treated with either 50 nM of myriaporone 3/4 (panel B) or methanol which 
served as control (A) for 4 hours and stained with phospho-eEF2 antibody (green). Cells 
treated with myriaporone 3/4 showed an increased phosphorylation compared to the control. 
Scale bar 50 µm. 
 
To reconfirm the above effect KB-3-1 cells were treated with 1 µM, 0.1 µM and 
0.01µM myriaporone 3/4 for 6 hours. The cell lysate was subjected to western blot 
and probed with phosphorylated eEF2, total eEF2 and GAPDH. GAPDH served as a 
loading control. As can be seen from Fig. 3.27, cells treated with myriaporone 3/4 
showed an increased level of phosphorylation when compared to the control. Thus, it 
is clear that myriaporone 3/4 inhibits translation by inducing phosphorylation of eEF2.  
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Figure 3.27: Myriaporone 3/4 induces phosphorylation of eEF2 
KB-3-1 cells treated with myriaporone 3/4 at various concentrations for 4 hours show an 
increase in the phophorylation of eEF2 compared to methanol treated cells. There is no 
change in the total eEF2 in treated cells compared to the control cells. 
 
3.3.9 Effect of myriaporone 3/4 on eEF2K 
As seen in the previous chapter (Section 3.3.8) myriaporone induces phosphorylation 
of eEF2. The kinase known to phosphorylate eEF2 is eEF2K. For eEF2K to be active 
it has to be de-phosphorylated at Ser 366. Therefore, lysates from KB-3-1 cells 
treated with 1 µM, 0.1 µM, and 0.01 µM of myriaporone 3/4 were subjected to western 
blot and probed with anti-phosphorylated eEF2K and anti-total eEF2k antibodies. As 
can be seen from Fig. 3.28, myriaporone 3/4 did not alter the phosphorylation of 
eEF2K.  
 
 
 
 
Figure 3.28: Myriaporone 3/4 does not induce eEF2K de-phosphorylation 
KB-3-1 cells treated with myriaporone 3/4 at various concentrations for 4 hours did not show a 
difference in phosphorylation when compared to cells treated with methanol (control). 
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3.3.10 Target of myriaporone 3/4 
Since myriaporone 3/4 does not alter the phosphorylation state of eEF2K, it was 
hypothesised that myriaporone could bind to eEF2K and thus activate. To investigate 
this hypothesis a DARTS approach was carried out with cell lysates treated with 
myriaporone 3/4 at different concentrations (1 µM, 0.1 µM, 0.01 µM). A cell lysate 
treated with methanol was used as negative control and a cell lysate treated with 
myriaporone but not subjected to pronase digestion was used as positive control. It is 
clear from the Fig. 3.29 that eEF2K of cell lysates treated with myriaporone were 
significantly protected from pronase digestion in comparison to the positive control 
whereas the eEF2K cell lysates treated with methanol only were not protected and 
almost completely digested by pronase. The membrane was also probed with anti-
eEF2 antibody to check if myriaporone 3/4 binds to eEF2. It can be seen from 
Fig. 3.29 that eEF2 was not protected by pronase digestion as it was digested to the 
same extent as the negative control. 
Pronase + - + + + 
Myriaporone 3/4 - + + + + 
µM 0 1 1 0.1 0.01 
 
 
 
 
Figure 3.29: Myriaporone binds to eEF2K directly. 
KB-3-1 cell lysates treated with myriaporone 3/4 or methanol was subjected to pronase 
digestion. Western blot was performed with the lysates. Myriaporone 3/4 protected eEF2K 
from pronase digestion in a dose dependant manner, whereas the methanol treated lysates 
were digested completely. eEF2 on the other hand was not protected by myriaporone 3/4. 
 
To reconfirm that myriaporone 3/4 has a direct effect on eEF2K, rabbit reticulocyte 
lysate was supplemented with an eEF2K enriched lysate or an empty vector lysate 
from HEK2 cells. An in vitro translation assay was performed by adding luciferase 
mRNA and various concentrations of myriaporone 3/4 (0.01 to 1000 µM) to the above 
enriched lysates. The reaction mixture supplemented with an eEF2K enriched cell 
eEF2K 
eEF2 
GAPDH 
Results 
 
[77] 
 
lysate had an IC50 of 80 µM and the reaction mixture enriched with the empty vector 
had an IC50 of 3 µM (Fig. 3.30). These results also confirmed that the target of 
myriaporone is eEF2K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: Effect of myriaporone on eEF2K enriched lysates 
Rabbit reticulocyte lysates were incubated with an eEF2K overexpression cell lysate or a cell 
lysate with an empty vector and varying concentration of myriaporone. The eEF2K enriched 
lysate had an higher IC50 than the empty vector. 
 
 
 
 
 
 
 
Myriaporone (µM)
0.01 0.1 1 10 100 1000
Lu
m
in
e
sc
e
n
ce
 
(%
 
co
n
tro
l)
0
20
40
60
80
100
120
140
eEF2K enriched lysate
empty vector enriched lysate
Results 
 
[78] 
 
3.4 Identification of mode action of des-epoxy tedanolide  
In Sections 3.1.3 and 3.1.4 it has been reported that des-epoxy tedanolide inhibited 
translation both in vitro and in cells in nanomolar ranges. However, the mechanism of 
the inhibition and its target still had to be elucidated. The following sections deal with 
the mechanism of translation inhibition by des-epoxy tedanolide. 
3.4.1 Analysis of des-epoxy tedanolide cytotoxicity by FACS 
To test the kinetics of cell death induction by des-epoxy tedanolide, A-431 cells were 
treated with 50 nM of polyketide for 3, 6, 12 and 24 hours. The induction of apoptosis 
in the cells was measured by flow cytometry (FACS). Methanol treated cells were 
used as control. Fig. 3.31 shows that after 6 hours of treatment with des-epoxy 
tedanolide, 30 % of the cells had undergone apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: FACS analysis of A-431 cells treated with des-epoxy tedanolide 
42.5% of the treated cells had undergone apoptosis after 24 hours compared to 4.5 % of cells 
treated with methanol for 24 hours. 
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3.4.2 Des-epoxy tedanolide inhibits angiogenesis 
As mentioned earlier translation inhibitors have been shown to inhibit angiogenesis. 
To test des-epoxy tedanolide for such an activity, HUVECs plated in Matrigel® were 
treated with des-epoxy tedanolide in the concentration range of 1.0 – 0.001 µM. 
Des-epoxy tedanolide inhibited tube formation with an MIC of 3.6 nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: Des-epoxy tedanolide inhibits formation of tubes in vitro 
HUVECs plated on Matrigel were treated with various concentrations of des-epoxy tedanolide. 
Panel B (100 nM), panel C (3.6 nM) and panel D (0.1 nM) are representative figures. Panel A 
shows cells treated with the vehicle methanol only.  
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3.4.3 Mechanism of des-epoxy tedanolide induced translation 
inhibition 
Candidaspongiolide, a member of the tedanolide family (see Section 1.6.2), has been 
shown to inhibit translation by inducing phosphorylation of eIF2α. To test if des-epoxy 
tedanolide induces phosphorylation of eIF2α, PtK2 cells cultured on cover slips in 
4-well plates were treated with 50 nM of des-epoxy tedanolide for 4 hours. The cells 
were fixed and stained with mouse anti-eIF2α and rabbit anti-phospho-eIF2α. Cells 
treated with methanol served as control. As can be seen from Fig. 3.33, cells treated 
with des-epoxy tedanolide showed an increased level of phosphorylation of eIF2α 
when compared to the control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: Des-epoxy tedanolide induces phosphorylation of eIF2α 
Cultured PtK2 cells were treated with des-epoxy tedanolide or methanol for 4 hours, fixed and 
stained with anti-eIF2α antibody (red) and anti-phospho-eIF2α antibody (green). Des-epoxy 
tedanolide induced phosphorylation of eIF2α as seen from increased green fluorescence. 
Scale bar: 10 µm.  
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3.4.4 Effect of des-epoxy tedanolide on translation initiation 
As mentioned earlier, CrPV IRES does not require initiation factors for the formation of 
the 80S initiation complex. Since des-epoxy tedanolide induces phosphorylation of 
eIF2α it was hypothesised that the CrPV IRES translation would not be inhibited by 
des-epoxy tedanolide. Therefore, KB 3-1 cells transfected with the CrPV bicistronic 
vector were treated with des-epoxy tedanolide, cycloheximide and pateamine A at 
concentrations ranging from 1 - 0.01 µM for 3 hours. The luminescence generated 
from the two luciferases was measured. Des-epoxy tedanolide and cycloheximide 
inhibited the translation of Renilla and firefly luciferase reporter systems equally 
(Fig. 3.34). On the other hand, pateamine A which inhibits the initiation phase of 
translation inhibited only the luminescence from the firefly luciferase and the Renilla 
luciferase encoded by the CrPV IRES was uninhibited. This suggests that des-epoxy 
tedanolide could have another target in the translation system apart from eIF2α. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34: Des-epoxy tedanolide inhibits translation initiation 
Des-epoxy tedanolide (A) and cycloheximide (B) inhibited the translation of the Renilla 
luciferase coded by the CrPV IRES (white bars) similarly to the cap-dependant translation of 
the firefly luciferase (black bars). Pateamine A which targets eIF4A inhibited the cap-
dependant translation only. 
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3.4.5 Effect of des-epoxy tedanolide on eIF4 complex 
Though des-epoxy tedanolide inhibited the CrPV IRES dependant translation, it still 
could target eIF4E or eIF4G. To determine if des-epoxy tedanolide targets these two 
factors, the bicistronic system as mentioned in Section 3.2.6 which consisted of firefly 
luciferase translated by a cap-dependant system and Renilla luciferase translated by 
polio IRES systems was used. Polio IRES does not require eIF4E and eIF4G for 
translation initiation. KB 3-1 cells transfected with the above vectors were treated with 
des-epoxy tedanolide, pateamine A and cycloheximide at concentrations ranging from 
1.0 - 0.01 µM for 3 hours. The luminescence generated from the two luciferases was 
measured. Cycloheximide, which stalls the elongation phase, inhibited the translation 
of Renilla and firefly luciferase from the reporter systems equally whereas pateamine 
A only inhibited the firefly and not the Renilla luminescence as it inhibits eIF4A. Des-
epoxy tedanolide 3/4 inhibited the translation of the polio IRES and the cap-
dependent translation systems equally similarly to cycloheximide (Fig. 3.35).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35: Des-epoxy tedanolide does not disrupt eIF4 complex 
Des-epoxy tedanolide (A) like cycloheximide (B) and pateamine A (C) inhibited the translation 
of the Renilla luciferase coded by the polio IRES (white bars) similarly to the cap-dependant 
translation of the firefly luciferase (black bars). 
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3.4.6 Role of des-epoxy tedanolide in eEF2 inactivation 
Although des-epoxy tedanolide induced the phosphorylation of eIF2α, it inhibited the 
translation of the CrPV IRES. This suggested that des-epoxy tedanolide could have a 
secondary target in the translation system. To test this hypothesis, PtK2 cells were 
treated with 50 nM of the polyketide and incubated for 4 hours. The cells were then 
fixed and stained for phosphorylated eEF2. Cells treated with methanol served as 
control. Des-epoxy tedanolide induced phosphorylation of eEF2 as can be seen from 
increased red fluorescence (Fig. 3.36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: Des-epoxy tedanolide induces phosphorylation of eEF2 
PtK2 cells were treated either with methanol (A) or 50 nM of des-epoxy tedanolide (B) for four 
hours. The cells were fixed and stained for phospho-eEF2 (red). Des-epoxy tedanolide 
induced phosphorylation of eEF2 (A) compared to methanol treated cells (B) which served as 
control. Scale bar: 10 µm. 
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3.4.7 Mechanism of eEF2 phosphorylation by des-epoxy tedanolide 
As seen in the previous chapter (Section 3.4.6) des-epoxy tedanolide induced 
phosphorylation of eEF2. The only kinase known to phosphorylate eEF2 is eEF2K. 
For eEF2K to be active it has to be de-phosphorylated at Ser 366. To check if des-
epoxy tedanolide reduces eEF2K phosphorylation (Ser 366), PtK2 cells were cultured 
on coverslips in 4-well plates for 16 hours and treated with 50 nM of des-epoxy 
tedanolide for 4 hours. The cells were fixed and stained for phospho-eEF2K. As can 
be seen from Fig. 3.37, des-epoxy tedanolide induced dephosphorylation of eEF2K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37: Des-epoxy tedanolide induces dephosphorylation of eEF2K 
PtK2 cells were treated with methanol (A) which served as control or des-epoxy tedanolide (B) 
for 4 hours. The cells were fixed and stained with phospho-eEF2K (Ser 366). Des-epoxy 
tedanolide induced dephosphorylation of eEF2K thus making it active. Scale bar: 10 µm 
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3.5 Identification of mode action of aetheramide B 
Sections 3.1.3 and 3.1.4 reported that aetheramide B inhibits translation both in vitro 
and in cells in nanomolar ranges. The following section deals with the mechanism of 
translation inhibition by des-epoxy tedanolide and also reports its target protein within 
the cell. 
3.5.1 Aetheramide B inhibits angiogenesis 
To test if aetheramide B inhibits angiogenesis, HUVECs plated in Matrigel® were 
treated with aetheramide B in the concentration range of 1.0 – 0.0003 µM. It was 
observed that aetheramide B inhibited tube formation with an MIC of 0.04 µM 
(Fig. 3.38). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38: Aetheramide B inhibits tube formation of tubes in vitro 
HUVECs plated on Matrigel were treated with various concentrations of aetheramide B. Panel 
B (1.0 µM), panel C (0.04 µM) and panel D (0.1 nM) are representative figures. Panel A shows 
cells treated with the vehicle methanol only. Scale bar: 50 µm. 
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3.5.2 Effect of aetheramide B on translation initiation 
Since it had been shown that aetheramide B was a translation inhibitor, the next step 
was to identify the phase of translation which aetheramide B targets. To test if 
aetheramide B targets the translation initiation phase the CrPV bicistronic vector was 
used. As mentioned before, CrPV IRES does not require any of the initiation factors. If 
the translation of IRES dependant Renilla luciferase is not inhibited then it suggests 
that aetheramide B targets the initiation phase.  
KB-3-1 cells transfected with the CrPV bicistronic vector were treated with 
aetheramide B, cycloheximide and pateamine A at concentrations ranging from 10 - 
0.01 µM for 3 hours. The luminescence generated from the two luciferases was 
measured. Cycloheximide, which stalls the elongation phase, inhibited the translation 
of Renilla and firefly luciferase reporter systems equally (Fig. 3.39). On the other 
hand, pateamine A which inhibits the initiation phase of translation inhibited only the 
luminescence from the firefly luciferase, whereas the Renilla luciferase encoded by 
the CrPV IRES was uninhibited. Aetheramide B inhibited the luminescence only from 
the firefly luciferase. The Renilla luciferase was uninhibited similar to the results 
obtained with pateamine A suggesting that the target of aetheramide B lies in the 
initiation phase. 
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Figure 3.39: Aetheramide does not inhibit CrPV IRES 
Aetheramide B (C) like pateamine A (A) inhibited only the cap-dependant translation (black 
bars) and not the cap-independent translation (white bars) whereas cycloheximide (B) inhibited 
both the translation systems equally. 
 
3.5.3 Effect of aetheramide B on eIF4 complex 
From the previous section it was clear that aetheramide B targets the initiation phase 
of translation. To test the possibility that aetheramide B could target either eIF4E or 
eIF4G, the bicistronic polio IRES vector was used. Polio IRES does not require eI4E 
and eIF4G for translation initiation. Therefore if aetheramide does not inhibit polio 
IRES dependant translation of Renilla luciferase then it would suggest that 
aetheramide B targets eIF4 complex. To determine if aetheramide B targets the eIF4 
complex, KB-3-1 cells transfected with the polio bicistronic vector was treated with 
aetheramide B, cycloheximide and pateamine A at concentrations ranging from 10 - 
0.01 µM for 3 hours. The luminescence generated from the firefly luciferase 
representing the cap-dependant translation and Renilla luciferases representing the 
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cap-independent translation were measured. Cycloheximide, which stalls the 
elongation phase, and pateamine A, which targets eIF4A, inhibited the translation of 
Renilla and firefly luciferase reporter systems equally (Fig. 3.40). In contrast to it 
aetheramide B inhibited the luminescence only from the firefly luciferase suggesting 
that the target of aetheramide B lies either in eIF4E or eIF4G. 
 
 
 
 
 
 
 
 
Figure 3.40: Aetheramide B targets either eIF4E or eIF4G 
Aetheramide B (C) did not inhibit the cap-independent translation (white bars) but only the cap-
dependent translation (white bars). Pateamine A (A) and cycloheximide (B) inhibited both the 
translation systems. 
 
3.5.4 Mechanism of inhibition of translation initiation by aetheramide B  
Aetheramide B does not inhibit the translation of neither CrPV IRES nor polio IRES. 
This suggests that the possible target of aetheramide B lies either in eIF4E or in 
eIF4G of the eIF4 complex. As mentioned in the Section 1.2.7, eIF4E can be 
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regulated by the phosphorylation of 4E-BP. To test if aetheramide B alters the 
phosphorylation state of 4E-BP, KB-3-1 cells were treated with aetheramide B for 6 
hours. The lysed cells were subjected to SDS PAGE followed by western blotting and 
probed with anti-phosphorylated 4E-BP (Thr 37/46) antibody. Cells treated with 
methanol served as negative control. Cells treated with LY294002, a known PI3K 
inhibitor, were used as positive control. As can be seen from Fig. 3.41, aetheramide B 
induced dephosphorylation of 4E-BP similar to LY294002. 
 
 
 
 
 
 
Figure 3.41: Aetheramide induces dephosphorylation of 4E-BP 
KB-3-1 cells were treated with either methanol (lane 1), LY294002 (Conc.2.5 µM; lane 2), 
aetheramide B (1 µM; lane 4) or aetheramide B (100 nM; lane 3) for 6 hours and subjected to 
western blotting.  The blotted membrane was probed with anti-phospho-4E-BP antibody. Cells 
treated with aetheramide B showed dephosphorylation of 4E-BP like the positive control (lane 
2). GAPDH served as a loading control. 
 
3.5.5 Aetheramide B inactivates mTOR 
The phosphorylation state of 4E-BP is regulated by the mTOR pathway. 4E-BP is 
dephosphorylated if mTOR is inhibited. The inhibition of mTOR leads to 4E-BP 
dephosphorylation (Jackson et al., 2010). To test if mTOR is inhibited by aetheramide, 
KB-3-1 cells were treated with aetheramide B (1 µM, 100 nM) for 6 hours. Cells 
treated with 6 µM of LY294002, a known inhibitor of PI3K, were used as a positive 
control. Cells treated with methanol served as a negative control. The cells were then 
lysed and subjected to SDS-PAGE followed by western blot. The blotted membrane 
was then probed with an anti-phospho mTOR (Ser 2448) antibody. As can be seen 
from Fig. 3.42, cells treated with aetheramide and LY294002 show reduced 
phosphorylation as compared to cells treated with methanol only.  
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Figure 3.42: Aetheramide B inhibits mTOR pathway 
KB-3-1 cells were treated with either methanol (ane 1), LY294002 (con:2.5 µM, lane 2), 1 µM 
aetheramide B (lane 3) or 100 nM aetheramide B (lane 4) for 6 hours and subjected to western 
blotting. The blotted membrane was probed with an anti-phospho-mTOR (Ser 2448) antibody, 
an anti-mTOR and an anti-GAPDH antibody. Cells treated with aetheramide B show reduction 
in the phosphorylation of mTOR like the positive control (lane 2).The total mTOR protein 
remained unchanged. GAPDH served as a loading control. 
 
3.5.6 Induction of stress granules by aetheramide B  
Aetheramide B induces dephosphorylation of 4E-BP. As a result eIF4E is not 
available for the formation of an eIF4F complex. This should result in the formation of 
stress granules. Hence investigating stress granules formation helps to further confirm 
the target of aetheramide B. To examine if aetheramide B induces stress granules, 
PtK2 cells were cultured for 16 hours on cover slips in a 4-well plate. The cells were 
treated with 100 nM of aetheramide B for 4 hours then, fixed and stained for TIA, an 
RNA binding protein, which served as a marker for stress granules. The cells were 
also stained for eIF4E. Pateamine A (20 nM) (a known stress granule inducer) was 
used in positive control cells (Low et al., 2005) (Fig. 3.43). The results showed that 
aetheramide B indeed induced the formation of stress granules.  
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Figure 3.43: Aetheramide B induces stress granule formation 
Cultured PtK2 cells were treated with methanol (top row), 100 nM aetheramide B (middle row) 
or pateamine A (bottom row) for 4 hours. The cells were fixed and stained for eIF4E (green) 
and TIA (red). Aetheramide B like pateamine A induced stress granules. The arrows indicate 
stress granules in the cells. Scale bar: 50 µm. 
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4 Discussion 
The molecular mechanism of eukaryotic translation is exceedingly complex and only 
partially understood as of now. The current knowledge of eukaryotic translation is 
extrapolation of the knowledge from the prokaryotic system. However, the prokaryotic 
system varies largely from the eukaryotic translation apparatus. This is clear from the 
fact that most prokaryotic translation inhibitors are ineffective in the eukaryotic system 
(Jackson et al., 2010; Poehlsgaard and Douthwaite, 2005; Schroeder et al., 2007; Tu 
et al., 2005) . Hence there is a dire need for specific eukaryotic translation inhibitors to 
elucidate the translation machinery. It is clear that protein synthesis is vital for the 
survival of the cells, but it has also been shown that small molecules targeting the 
translation system are potential antivirals and anti-tumour agents. Considering the 
above reasons it is of great importance to find and study the mode of action of 
translation inhibitors specific to eukaryotes (Chan et al., 2004). Eukaryotic translation 
inhibitors can stall translation by three different mechanisms: i) by depleting the 
substrates that are required for the translation, ii) by directly or indirectly targeting the 
factors involved in translation, and iii) by binding to the ribosome directly and 
inactivating them (Sonenberg and Hinnebusch, 2009). 
The central objective of this study was to elucidate the mode of action of four small 
molecules that are translation inhibitors of the eukaryotic systems viz. gephyronic 
acid, myriaporone 3/4, des-epoxy tedanolide and aetheramide B. The first three 
polyketides have been reported as translation inhibitors earlier whereas aetheramide 
B was identified as a translation inhibitor in the course of this study. In the following 
the results of the four polyketide translation inhibitors are discussed.  
4.1 Polyketides inhibit eukaryotic translation 
Gephyronic acid, myriaporone 3/4, des-epoxy tedanolide and aetheramide B inhibited 
the growth of cancer cells in the nanomolar ranges. They also inhibited the growth of 
eukaryotic micro-organisms like S. cerevisiae and C. albicans as reported earlier 
(Hines et al., 2006; Plaza et al., 2012; Sasse et al., 1995; Taylor, 2008). In line with 
the earlier reports gephyronic acid, myriaporone 3/4 and des-epoxy tedanolide did not 
inhibit the growth of any of the prokaryotes used in this study. Gephyronic acid, des-
epoxy tedanolide and myriaporone 3/4 were already established as translation 
inhibitors. Consistent with the previously published results, the three polyketides 
proved to be translation inhibitors with an IC50 of 0.07 µM (gephyronic acid), 0.4 µM 
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(myriaporone 3/4), 0.01 µM (des-epoxy tedanolide) in the in vitro rabbit reticulocyte 
translation system and 30 nM (gephyronic acid), 100 nM (myriaporone 3/4), and 0.2 
nM (des-epoxy tedanolide) in KB-3-1 cells. Aetheramide B is a novel translation 
inhibitor reported for the first time in this study. It inhibited translation with an IC50 of 
1.1 µM in the in vitro translation and 700 nM in KB-3-1 cells.  
4.2 Mechanism of translation inhibition by the polyketides 
4.2.1 Gephyronic acid 
It has been shown by a number of studies that induction of apoptosis by various 
stimuli could lead to inhibition of protein synthesis (Clemens et al., 2000). Therefore 
A-431 cells were treated with gephyronic acid and analysed for apoptosis at various 
time points. However, from the results (Fig. 3.3) it is clear that after 6 hours of 
treatment with 50 nM gephyronic acid only 16.2% cells had undergone apoptosis 
whereas at the same concentration after 4 hours there was a translation inhibition of 
more than 40% (Fig. 3.2) This indicated that translation inhibition precedes apoptosis. 
The cells underwent apoptosis as a result of translation inhibition. Also the correlation 
between the IC50 of cellular cytotoxicity and cellular translation holds proof that 
gephyronic acid is indeed a translation inhibitor as reported previously (Sasse et al., 
1995). The cytotoxicity of gephyronic acid was partially reversible at lower 
concentrations and only when incubated not longer than 6 hours. Incubation at higher 
concentration or for longer time periods with gephyronic acid induced an irreversible 
cytotoxicity. This suggests that gephyronic acid induces apoptosis only as result of 
translation inhibition unlike compounds like pateamine A. In case of pateamine A 
caspase 3 induced cleavage of translation factors was reported to be an additional 
reason for translation inhibition (Hood et al., 2001). 
Gephyronic acid inhibited the translation of the cap-dependant IRES. However, it did 
not inhibit the translation of Renilla luciferase encoded by the CrPV IRES (Fig. 3.9). 
As reported by others, pateamine A which targets the initiation phase inhibited only 
cap-dependant translation. Cycloheximide, on the other hand inhibited the translation 
of both cap-dependent and cap-independent translation equally as reported earlier 
(Schneider-Poetsch et al., 2010). This confirmed that the target of gephyronic acid lies 
within the initiation phase as CrPV IRES does not require any of the initiation factors. 
Also, gephyronic acid inhibited the translation of the Renilla luciferase encoded by the 
polio IRES (Fig. 3.10). This eliminated the possibility that target of gephyronic acid 
could lie with either eIF4E or eIF4G. From the chemo genetic interaction screening, 
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the target was further shortlisted to the eIF2 complex. With the help of a DARTS 
approach, the direct target of gephyronic acid was identified to be eIF2α. Pull down 
assays and immunofluorescence studies confirmed that gephyronic acid binds directly 
to eIF2α. The affinity of gephyronic acid for eIF2α is strong as can been seen from the 
western blots of the pull down assay. Previously, compounds like salubrinal and 
#1181 have been shown to have an effect on eIF2α (Boyce et al., 2005; Natarajan et 
al., 2004). Salubrinal inhibited de-phosphorylation of eIF2α whereas #1181, induced 
phosphorylation by activating PERK. PERK is an eIF2α kinase which is activated 
when Ca2+ is depleted (Harding et al., 1999). In both cases the effect of the 
compounds on eIF2α is only indirect effect. So gephyronic acid is the first small 
molecule that binds to eIF2α directly.  
It was shown that gephyronic acid is 100 fold less active in primary cells (NHDF) when 
compared to the cancerous KB-3-1 cells. This may not be due to the differences in the 
sensitivities of different cell lines to apoptosis rather due to alterations in the 
translation apparatus. Some cancers like colon cancer have shown to overexpress 
eIF2α (Rosenwald et al., 2003). There could be an inherent alteration in eIF2α of 
cancer cells making them more sensitive to treatment with gephyronic acid. It could 
also be possible that gephyronic acid does not target eIF2α of primary cell lines. This 
was reported in case of candidaspongiolide which inhibits translation by 
phosphorylation of eIF2α. However, candidaspongiolide did not induce 
phosphorylation of eIF2α in primary fibroblast cells (Trisciuoglio et al., 2008). This 
could also be possible in the case of gephyronic acid. 
Recent studies showed that inhibition of translation can inhibit angiogenesis in 
tumours (Cencic et al., 2009; Graff et al., 2007). Here, the results show that 
gephyronic acid inhibited the tube formation by HUVECs. This is in correlation with 
previously published data with translation inhibitors like Didemnin B and cytotrienin A 
(Lindqvist et al., 2010). Further studies are required to show if gephyronic acid can 
inhibit angiogenesis in vivo. 
In line with previous publication by Sasse et al., (1995), gephyronic acid was shown to 
be cytotoxic only in eukaryotes and not in prokaryotes. Translation inhibition assays 
with E. coli S30 extracts shows that gephyronic acid failed to inhibit translation of the 
luciferase mRNA, whereas, gephyronic acid inhibited translation of luciferase mRNA 
in both wheat germ extract and in rabbit reticulocyte lysate extract. This shows that 
gephyronic acid is a specific eukaryotic translation inhibitor. Gephyronic acid could not 
inhibit the translation in the E. coli system which explains its inactivity in prokaryotes. 
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The reason that gephyronic acid did not inhibit the prokaryotic translation could be 
because its target eIF2α is conserved in eukaryotes and differs greatly from 
prokaryotic initiation factor 2 (Ito et al., 2004). An alignment of the amino acid 
sequence using ClustalW2 reveals that the amino acid sequence between position 6 
and 120 are highly conserved in eukaryotes (Fig 4.1). On the other hand, there is no 
sequence similarity between prokaryotes and eukaryotes.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Sequence alignment of eIF2α 
Protein sequence alignment of eIF2α from yeast, humans, rat and E. coli shows that amino 
acids at position 15, position 17 and position 39 (marked in green boxes) are different in 
eukaryotes and prokaryotes. The protein sequences for the alignment were obtained from 
UniProt. 
 
Also the amino acids which gephyronic acid binds to (Glu 15, Tyr 38) are different in 
eukaryotes and prokaryotes. Tyr 38 to which gephyronic acid strongly binds is 
conserved only among eukaryotic species. The other residues like Glu 14 and Asp 17 
present in eukaryotes are replaced by Thr 15 and Val 17 in E. coli. The differences in 
these residues possibly alter the binding affinity of gephyronic acid for eIF2α. As a 
result gephyronic acid does not have a target in the prokaryotic system making them 
least susceptible to gephyronic acid. 
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4.2.2 Myriaporone 3/4  
Myriaporone 3/4 was reported as a translation inhibitor (Hines et al., 2006). However 
their publication did not report the mechanism by which myriaporone 3/4 inhibits 
translation. During the course of this study, synthetic myriaporone 3/4 was used to 
elucidate the mode of action of the polyketide, which was was obtained from Prof. 
Rich Taylor, (Notre Dame, USA). As reported earlier myriaporone 3/4 proved to be 
cytotoxic in nanomolar ranges and also inhibited translation with a similar IC50. 
Results from the apoptosis study showed that myriaporone 3/4 (90 nM) induced 11 % 
cell death after 3 hours compared to 5 % cell death in the control. However, after 3 
hours of treatment with myriaporone 3/4 (90 nM), the translation was inhibited by 50 
% (in KB-3-1 cells). This clearly shows that apoptosis happens as a result of 
translation inhibition and not vice versa. This is also in line with the previous published 
results where myriaporone 3/4 caused delay in the S phase and then induced 
apoptosis (Hines et al., 2006).  
Myriaporone 3/4 inhibited the translation of Renilla luciferase translated by both polio 
and CrPV IRES similar to cycloheximide. This shows that myriaporone 3/4 does not 
target the initiation phase and the target possibly lies in the elongation and termination 
phase. Using a chemo genetic interaction screening the target was placed within the 
elongation phase (Table 3.4). Since the elongation factor 1 mutant did not show either 
increased or descried sensitivity compared to the wild type, elongation phase 2 was 
studied further. Though yeast has another elongation factor, eEF3 (Kamath and 
Chakraburtty, 1989), the mutant was not a viable one and hence could not be used in 
the screening. The well-established regulation mechanism within the elongation phase 
other than eEF1A inhibition is induction of eEF2 phosphorylation. When cells treated 
with myriaporone 3/4 were tested for the phosphorylation state of eEF2, they showed 
an increase in the phosphorylation of eEF2 (Fig. 3.26 and 3.27). The only kinase 
known to phosphorylate eEF2 was eEF2K. Therefore the phosphorylation state of 
eEF2K was analysed. However, the phosphorylation of eEF2K was not altered by the 
treatment with myriaporone 3/4. It was then hypothesised that myriaporone 3/4 binds 
directly to eEF2K thereby activating it. The results from a DARTS approach (Fig. 3.29) 
and a translation inhibition assay supplemented with enriched eEF2K lysate (Fig. 
3.30) showed that indeed myriaporone 3/4 binds directly to eEF2K. 
There has been previous reports of small molecules NH125 (synthetic) (Arora et al., 
2003), TS2 (Cho et al., 2000) and rottlerin isolated from Mallotus phillippinensis as 
inhibitors of eEF2K (Gschwendt et al., 1994). The potency of the above mentioned 
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compounds were in micromolar ranges. Myriaporone 3/4 on the other hand was 
potent in the nanomolar ranges making it the most potent eEF2K inhibitor. Rottlerin 
inhibits eEF2K by affecting the Ca2+ channels and inhibiting the protein kinase C 
(PKC) pathway (Gschwendt et al., 1994). Inactivation of PKC leads to the 
phosphorylation of eEF2 via eEF2K (Devost et al., 2008). Therefore the 
phosphorylation of eEF2 induced by rottlerin is only a secondary effect. NH125 was 
initially reported as direct inhibitor of eEF2K. This was later proved incorrect as 
NH125 induces phosphorylation of eEF2 via AMPK and competing with calmodulin for 
eEF2K (Chen et al., 2011). TS2 a synthetic small molecule inhibited by binding to 
eEF2K. TS2 binds to the ATP binding site (Cho et al., 2000). Thus, myriaporone 3/4 is 
the first natural compound to inhibit translation via direct interaction with eEF2K. 
Myriaporone 3/4 showed activity only in eukaryotes and did not have any cytotoxic 
effects in prokaryotes used in the screening (Table 3.2). This was also reported in 
earlier studies (Hines et al., 2006). This is probably due to the fact that prokaryotes do 
not have eEF2K. As myriaporone 3/4 does not have a target in the prokaryotic system 
it cannot inhibit translation of the prokaryotic system. 
Myriporone 3/4 showed at least 300 fold less cytotoxicity in primary cells when 
compared to cancerous KB-3-1 cells even after 72 hours treatment. This could be due 
better uptake of myriaporone 3/4 by cancer cells due to their increased metabolism. It 
has also been shown that phosphorylation of eEF2 can lead to ER stress (Boyce et 
al., 2008). As the cancer cells are already under stressed conditions even a slight 
increase could be deleterious to their survival. As a result the ER stress could 
probably lead to increased apoptosis. Further investigations are still required to 
assess the difference in cytotoxicity induced by myriaporone 3/4 in cancer and 
primary cells. Also if this difference could be extrapolated to in vivo models have to be 
studied.  
Myriaporone 3/4 inhibits angiogenesis as shown by HUVECs in the tube formation 
assay in nanomolar ranges. Cytotrienin A, a previously reported translation elongation 
inhibitor inhibited tube formation in micromolar ranges (Lindqvist et al., 2010). Thus 
myriaporone 3/4 proves to be a more potent angiogenesis inhibitor. Though 
myriaporone 3/4 is less toxic to primary cells it inhibits the formation of vessels by 
HUVECs on Matrigel®. This is plausible as it has been shown that induction of 
phosphorylation of eEF2 inhibits migration of endothelial cells (Khan et al., 2010). 
Though myriaporone 3/4 does not show cytotoxicity to a greater extent in primary 
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cells, it inhibits the migration of HUVECs which subsequently lead to the inhibition of 
angiogenesis. 
eEF2K is overexpressed in most cancers (Chen et al., 2011). As a result binding of 
myriaporone 3/4 to eEF2K could activate it thus inducing phosphorylation of eEF2 and 
finally inhibiting translation. eEF2K is also involved in the switch between apoptosis 
and autophagy (Cheng et al., 2012; Hait et al., 2006). Inhibiting eEF2K would inhibit 
the signalling required for autophagy and thus lead to cell death. Cheng et al. (2012), 
reported that inhibiting eEF2K causes the tumour cells undergo apoptosis rather than 
switch to autophagy. Considering the above statements it is clear that myriaporone 
3/4 has a potential to be used as a potent anti-cancer agent. 
4.2.3 Des-epoxy tedanolide 
Des-epoxy tedanolide is a synthetic analogue of 13-desoxy tedanolide (Diaz et al., 
2012b). The only difference is the lack of epoxide at C17. It has been shown 
previously that the conformation is controlled by the configuration at C15 and C5. It 
has been proposed that the removal of the epoxide decreases the activity of the 
compound by at least a hundred fold (Hines et al., 2006; Taylor, 2008). However, des-
epoxy tedanolide shows only one fold difference (reduction) in cytotoxicity when 
compared to 13-deoxy tedanolide (Diaz et al., 2012b). Thus the epoxide may not be 
as important for its activity as proposed earlier. Also the epoxide was predicted to be 
necessary for the formation of covalent bonds (Hines et al., 2006; Taylor, 2008). Thus 
the role of the epoxide in 13-desoxytedanolide requires further investigations. 
The des-epoxy tedanolide was provided by Prof. Markus Kalesse (Hannover, 
Germany). Des-epoxy tedanolide was active only in eukaryotes and did not inhibit the 
growth of prokaryotes. This also draws a parallel with the published result that des-
epoxy tedanolide inhibits only the eukaryotic translation and not the prokaryotic 
translation. It has been shown that 13-desoxy tedanolide binds to the 60S ribosome 
and induces ribotoxic stress by binding to 60S ribosome (Schroeder et al., 2007). 
However, it has been suggested that ribotoxic stress cannot induce cell death with 
such great potency as 13-desoxtedanolide does. Therefore another mechanism must 
be responsible for the potency of 13-desoxtedanolide in addition to induction of 
ribotoxic stress. Candidaspongiolide, a member of the tedanolide family (Fig. 1.15) 
showed that it induced cell death by stalling translation. Candidaspongiolide inhibited 
translation by inducing phosphorylation of eIF2α (Meragelman et al., 2007). When 
des-epoxy tedanolide treated cells were tested for the phosphorylation of eIF2α, the 
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cells showed an increased level of eIF2α phosphorylation. However, the mode of 
phosphorylation of eIF2α is yet to be identified. eIF2α can be phosphorylated by 4 
different kinases viz. GCN2, PKR, PERK and HRK (Jackson et al., 2010). So further 
studies need to be carried out to find the kinase involved in the phosphorylation of 
eIF2α. The increased phosphorylation of eIF2α in cells when treated with des-epoxy 
tedanolide could also because of the inhibition of GADD34, an eIF2α 
dephosphorylase as seen in the case of salubirinal (Boyce et al., 2005). This is yet to 
be investigated.  
A bicistronic vector was used to locate the translation phase that des-epoxy 
tedanolide targets. Des-epoxy tedanolide inhibited the translation of both CrPV and 
polio IRES dependent translation (Fig. 3.34, 3.35). As des-epoxy tedanolide induces 
phosphorylation of eIF2α it was expected that it would inhibit polio IRES dependant 
translation. However, it also inhibited the translation of CrPV IRES which does not 
require any of the initiation factors. Therefore it was proposed that there should be 
another target either in the elongation or in the termination phase of translation.  
The yeast mutant collection could not be used for chemo genetics studies as 
des-epoxy tedanolide did not inhibit the growth of S.cerivesiae. Therefore the 
phosphorylation state of eEF2 was analysed. It was seen that des-epoxy induced 
phosphorylation of eEF2 though the eEF2K. It has been reported recently that 
salubrinal, an eIF2α phosphorylation inducer, induces phosphorylation of eEF2 via the 
AMPK pathway. Phosphorylation of eIF2α can lead to ER stress which in turn leads to 
eEF2 phosphorylation (Boyce et al., 2008). Therefore the induction of eEF2 
phosphorylation may not be an direct effect of des-epoxy tedanolide.  
Des-epoxy tedanolide also inhibited the tube formation of HUVECs plated on 
Matrigel®. The inhibition of translation could be because of two reasons. Firstly, 
des-epoxy tedanolide is a potent cytotoxic compound with an IC50 of 1.6 nM. As result 
of this it could be inducing apoptosis in HUVECs which in turn inhibits translation. 
Secondly, as mentioned earlier phosphorylation of eEF2 inhibits the migration of 
HUVECs which in turn inhibits tube formation.  
Des-epoxy tedanolide induces apoptosis in 33 % cells compared to 5 % in the control 
cells within six hours. This is significantly higher when compared to the two previous 
mentioned compounds viz. gephyronic acid and myriaporone 3/4. There are two 
plausible explanations for this. Firstly, des-epoxy tedanolide being more potent 
induces higher cell death rates. It has also been reported that the cytotoxicity induced 
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by it is irreversible even at lower concentrations which suggest that des-epoxy 
tedanolide could be forming a covalent bond with its target (Diaz et al., 2012b). As a 
result it has a significant higher potency. Secondly, 13-desoxytedanolide has been 
shown to induce ribotoxic stress (Lee et al., 2006). Des-epoxy tedanolide like 13-
desoxy tedanolide could induce stress granules in addition to the induction of 
phosphorylation of eIF2α and eEF2. Phosphorylation of eEF2 has shown to induce 
ER stress. The combination of ribotoxic stress, ER stress and translation inhibition 
could result in a greater potency of des-epoxy tedanolide. However, the induction of 
ribotoxic stress by des-epoxy tedanolide was not studied during the course of this 
study. It would be interesting to check if des-epoxy induces ribotoxic stress. 
4.2.4 Aetheramide B 
Aetheramide B is different from the other polyketides in this study as it has two amino 
acids within its structure. Plaza et al. (2010) reported the isolation of aetheramide A 
and B from myxobacteria. Though two isomers of aetheramide were reported, only 
aetheramide B was used for this study. The report did not mention anything about its 
mode of action. During the course of this study it was identified as a translation 
inhibitor. 
The cytotoxicity of aetheramide B in various cell lines was in the nanomolar range with 
an IC50 values between 15 to 40 nM. It was reported that aetheramide showed 
cytotoxicity with an IC50 of 110 nM in colon cancer cell lines. The results from this 
study show that aetheramide B is slightly more potent. This lower activity could be 
because the colon cells are more resistant to aetheramide B compared to the other 
cell lines used during the course of this study. 
As a routine screening in our laboratory suggested that aetheramide B could be a 
translation inhibitor, translation inhibition assays were performed with rabbit 
reticulocyte cell lysate and with KB-3-1 cells. Aetheramide B inhibited translation in 
KB-3-1 cells with an IC50 of 700 nM. To assess the phase of the translation targeted 
by aetheramide B, bicistronic vectors with either polio IRES or CrPV were used. 
Aetheramide B inhibited the translation of cap-dependant translation in both the vector 
transfected cells. However, it did not inhibit both the IRES dependant translation. This 
suggested that the target of aetheramide B lays within the initiation phase and either 
targets eIF4E or eIF4G.  
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If there is a disruption of the eIF4 complex, formation of stress granules is seen 
(Buchan and Parker, 2009). When cells treated with aetheramide B were tested for 
stress granules, they indeed showed the presence of stress granules. This confirmed 
that the eIF4 complex is targeted, either directly or indirectly. eIF4E is regulated by 
altering the phosphorylation of 4E-BP (Morino et al., 2000). Therefore the 
phosphorylation state of 4E-BP was tested. Dephosphorylation of 4E-BP was 
observed. The phosphorylation state of 4E-BP is regulated by mTOR. If mTOR is 
deactivated then 4E-BP is dephosphorylated (Jackson et al., 2010). Cells treated with 
aetheramide B showed reduced phosphorylation of mTOR suggesting that 
aetheramide B targets the mTOR pathway.  
There have earlier been reports on mTOR inhibitors. Rapamycin is a well-studied 
mTOR inhibitor. However, rapamycin is not an mTOR specific inhibitor. It has also 
been shown to inhibit phospho inositol-3-kinase (PI3K). Most of the other mTOR 
inhibitors reported are derivatives of rapamycin (rapalogs), for example temsirolimus 
(Del Bufalo et al., 2006). The current results with aetheramide B suggest that it 
deactivates mTOR pathway. However, it is unclear if the deactivation of mTOR by 
aetheramide is because it targets mTOR or if aetheramide has a target upstream of 
mTOR. Therefore the pathway upstream of the mTOR signalling has yet to be 
studied.  
Aetheramide B was also shown to inhibit angiogenesis in this study with an IC50 of 40 
nM. It was shown earlier that rapamycin could inhibit angiogenesis (Del Bufalo et al., 
2006). It has been reported by a number of researchers that PI3K/AKT/mTOR 
signalling is very critical for angiogenesis (Jazirehi et al., 2012; Nicoletti et al., 2011; 
Sheppard et al., 2012). Thus inhibiting the pI3K/AKT/mTOR pathway has a profound 
impact on HUVECs to form vessels both in vivo and in vitro. This explains the potent 
effect of aetheramide B in inhibiting the tube formation by HUVECs plated on 
Matrigel®. 
Aetheramide B inhibits HIV with an IC50 of 15 nM (Plaza et al., 2012). Recently it has 
been shown that during HIV infection the mTOR signalling pathway is up-regulated 
and leads to a hyper-phosphorylation of 4E-BP. This then led to the increase in the 
translation of proteins in HIV infected cells (Rehman et al., 2012). It was also reported 
that rapamycin possesses anti-HIV properties (Donia et al., 2010). This explains the 
inhibition of HIV proliferation by aetheramide B. The IC50 of translation inhibition by 
aetheramide was 0.7 µM, but aetheramide B inhibited HIV proliferation with an IC50 of 
15 nM. Thus the effect of aetheramide B on HIV proliferation is significantly higher 
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than its effect on translation inhibition. This could be because mTOR activation is very 
vital for HIV replication and even a slight deactivation of the mTOR signalling has a 
great impact on its replication (Nicoletti et al., 2011; Rehman et al., 2012). It could 
also be possible that aetheramide B has another target in the cell which is essential 
for HIV infection and replication. Thus, inhibiting multiple pathways required for HIV 
propagation, aetheramide B has a more profound effect on its proliferation and 
infection. 
4.3 Structurally similar but different targets 
 
 
 
 
 
 
 
 
 
Figure 4.2: Structural relationship between the polyketides 
The “southern hemisphere” of the three polyketides resembles each other. 
 
Three out of the four polyketides in this study are structurally similar viz. gephyronic 
acid, myriaporone 3/4 and tedanolide at the “southern hemisphere” (Taylor, 2008). As 
the three polyketides have structural similarities and the southern hemisphere was 
important for their function, it was proposed that they could have similar targets (Diaz 
et al., 2012a). Though myriaporone 3/4 and des-epoxy tedanolide induce 
phosphorylation of eEF2 it is through different mechanisms. Gephyronic acid on the 
other hand targets translation by binding to eIF2α. From the current results it is clear 
that these polyketides target different proteins or pathways irrespective of their 
structural similarity. 
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5 Outlook 
Our current understanding of the eukaryotic translation system is only half-done. The 
prokaryotic system is well characterised due to the availability of wide range of 
prokaryotic translation inhibitors. Identifying new eukaryotic inhibitors and elucidating 
their modes thus plays a critical role. This study identified four translation inhibitors 
that are specific to eukaryotes.  
All the four compounds in this study have shown to be specific eukaryotic inhibitors. 
And hence they can be used to study the eukaryotic translation better. Gephyronic 
acid inhibited translation by binding to eIF2α. This is the first compound that has been 
reported to do so. To understand the structural features of eIF2α better, a co-
crystallisation of gephyronic acid with eIF2α will be extremely valuable. Gephyronic 
acid can also help in understanding the role of eIF2α in translation initiation better. 
Myriaporone 3/4 is the first natural compound to target eEF2K directly. eEF2K is only 
partially understood and it is interesting to note that bacteria and yeast lack eEF2K. 
With the help of myriaporone 3/4 crystallisation of eEF2K which was not possible until 
now might be possible. This would give new insights into the regulation of the 
elongation phase. Aetheramide B inhibits the mTOR pathway. Further studies have to 
be carried out to test if it is a specific mTOR inhibitor. Aetheramide B was shown to 
inhibit HIV in vitro. However, there was a difference in its IC50 values of translation 
inhibition and viral inhibition. This suggests that there is a possible second target for 
aetheramide B.  
The four small molecules in this study were shown to have anti-cancer properties. 
They are cytotoxic to transformed cells, inhibit angiogenesis and hence they should 
be tested in vivo tumour models for their efficacy as a possible anti-cancer agent. 
Myriaporone 3/4 and gephyronic acid can be used to elucidate the role of eEF2K and 
eIF2α, in tumour progression. 
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